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CHAPTER 1. GENERAL INTRODUCTION 
Oxygen is required for most organisms to survive, and plays a critical role in the evolution of life 
(FALKOWSKI and GODFREY 2008; LINDAHL 2008). Oxidative phosphorylation is the most efficient 
way to generate biologically usable energy in the form of ATP. For most organisms, oxygen 
molecules are final electron acceptors in the oxidative phosphorylation reaction. However, hypoxia 
may occur where oxygen levels are too low to meet the cellular physiological demand. While oxygen 
concentration is usually 21% in room air, physiological nomoxia is much lower. For example, in the 
mammalian central nervous system (CNS), oxygen concentrations may range from 0.55% to 8% 
(PANCHISION 2009). Hypoxia often occurs in pathological conditions such as inflammation, stroke, 
anemia, ischemia, asthma, and solid tumors. However, it also occurs in normal physiological 
situations, such as during early embryonic development (DUNWOODIE 2009). The natural 
environment can be hypoxic as well. For example, at 5000 meters altitude, the oxygen pressure drops 
to about 50% of that at sea level (PEACOCK 1998). Organisms and cells have evolved a variety of 
ways to deal with and adapt to hypoxic stresses (BRAHIMI-HORN and POUYSSEGUR 2009; LAHIRI et 
al. 2006; WOUTERS and KORITZINSKY 2008). 
When hypoxia occurs, organisms or cells will often respond with a series of changes to survive. 
Most organisms have acute and chronic responses by which they decrease oxygen consumption and 
increase oxygen delivery (Figure 1). In mammals, acute responses, which normally take place within 
seconds, include increasing respiration rate, heart rate and dilation of blood vessels. These responses 
are mediated by a cluster of chemoreceptors in the carotid bodies (also called carotid glomus or 
glomus caroticum), located at the bifurcation of the carotid artery (LAHIRI et al. 2006). 
Chemoreceptors can detect changing oxygen partial pressure in the artery and pass that information to 
the central nervous system. There are several models to explain the oxygen sensing process in this 
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pathway, but the molecular mechanism is largely unknown (LAHIRI et al. 2006; LOPEZ-BARNEO et al. 
2006).  
Chronic responses include changes at transcriptional levels, largely mediated by prolyl 
hydroxylase domain proteins (PHDs) and the hypoxia inducible transcription factor (HIFs) pathways. 
This pathway is evolutionary conserved from nematode to humans (EPSTEIN et al. 2001; FANDREY 
and GASSMANN 2009; KAELIN and RATCLIFFE 2008; SEMENZA 2009; WEBB et al. 2009).  
During the eighteen years since HIF was identified, extensive work has been done with regard to 
the function and regulation of HIFs in a variety of organisms such as C. elegans (a nematode), 
Daphnia (a crustacean), Drosophila (an insect), and vertebrates. Some of the key regulators of 
hypoxia responses are conserved across phyla. Studies have also shown interesting differences in how 
different organisms adapt to hypoxia and how they regulate HIF (HAMPTON-SMITH and PEET 2009).  
This literature review focuses on HIFs and PHDs.  The first two sections summarize research on HIF 
and PHD regulation and function in mammals, and the final section reviews HIF-1/EGL-9 in C. 
elegans. 
 
LITERATURE REVIEW 
 
Hypoxia inducible factors in mammals 
The majority of gene expression changes in response to hypoxia are regulated by hypoxia 
inducible factors (HIFs). HIF transcription factors were first identified in 1992 by Semenza and Wang 
(SEMENZA and WANG 1992). In the study of erythropoietin (EPO) regulation in Hep3B cell line, they 
found that under hypoxic conditions EPO was upregulated by a nuclear factor they named HIF-1 
(hypoxia inducible factor 1) (SEMENZA and WANG 1992). HIFs are heterodimeric transcription 
factors that consist of oxygen insensitive β subunits and oxygen sensitive α subunits (BRAHIMI-HORN 
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and POUYSSEGUR 2009). The HIFβ is also called aryl hydrocarbon receptor translocator (ARNT), 
originally identified as an important factor in xenobiotic responses (HANKINSON 1995). Both α and β 
subunits have basic helix-loop-helix DNA binding domains and PAS (the name is from Drosophila 
Per and Sim, and mammalian ARNT) domains (WANG et al. 1995). HIFα also includes two ODDDs 
(oxygen dependent degradation domain) and two transactivation domains (N-TAD and C-TAD) in 
the C-terminus that are critical for HIFα protein stability and activity regulation (MASSON et al. 2001; 
PEREIRA et al. 2003; PUGH et al. 1997).  
There are three genes in mammals encoding HIFα subunits: HIF-1α, HIF-2α and HIF-3α (LISY 
and PEET 2008).  HIF-2α has also been referred to as HLF (HIF-1 like factor), HRF (HIF-1 related 
factor) and EPAS1 (Endothelial PAS domain protein 1) (EMA et al. 1997; FLAMME et al. 1997; TIAN 
et al. 1997). While HIF-1α is most likely broadly expressed at lower levels, HIF-2α expression is 
limited at certain stages and in some tissues. For example, HIF-2α is highly expressed in endothelium 
in embryos (EMA et al. 1997; FLAMME et al. 1997; TIAN et al. 1997). HIF-2α and HIF-1α share high 
sequence similarity, but they have both overlapping and distinct functions (HU et al. 2003; RAVAL et 
al. 2005; WANG et al. 2005). For example, using microarray analysis in HEK293T cell line, Wang et 
al. found that among 45 genes upregulated by HIF-1α or HIF-2α, 21 were regulated by both HIF-1α 
and HIF-2α; 14 were upregulated only by HIF-1α; and 10 were upregulated only by HIF-2α (WANG 
et al. 2005). Some HIF-3α splicing isoforms have only one TAD and also can dimerize with HIFβ 
(GU et al. 1998). Some isoforms do not have transactivation domains and probably function as a 
dominant negative regulator (MAKINO et al. 2002; MAYNARD et al. 2005). 
 
Survive or die, all HIFs’ matter: roles in embryonic development and pathophysiology: There are 
more than 200 genes directly or indirectly regulated by HIF (ELVIDGE et al. 2006; MANALO et al. 
2005). These genes function in decreasing oxygen consumption (enolase, aldolase c, etc.), increasing 
oxygen delivery (vascular endothelial growth factor, etc.), and determining cell fate (BNIP3, OCT-4, 
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etc). Generally, upregulation of these genes protects cells from hypoxia injury, or controls their 
identities. 
Oxygen concentration is very low during early embryo development before maternal and fetal 
blood connection is established (PRINGLE et al. 2007). During early embryonic development, HIF 
transcription factors play critical roles in vascular formation, trophoblast development, heart 
development, neural crest cell migration and endochondrial bone formation (DUNWOODIE 2009; 
PANCHISION 2009; SIMON and KEITH 2008). Mice completely lacking HIF-1α or HIF-2α die by the 
early development E11 stage (IYER et al. 1998; KOTCH et al. 1999; RYAN et al. 1998; TIAN et al. 
1998). Consistently, mutations of the dimerization partner ARNT also lead to embryonic lethality at 
similar stages (ADELMAN et al. 2000). 
HIF-1 was also found to play a critical role in inflammation (WALMSLEY et al. 2005). In 
inflamed environments oxygen concentration is usually <1% due to microvascular injury and 
thrombosis. HIF-1α accumulates in the inflamed environments (FREDE et al. 2005; FREDE et al. 2006; 
SITKOVSKY and LUKASHEV 2005). Cellular responses to hypoxia are particularly important for 
immune defense because in HIF-1α mutant macrophages and neutrophils have been shown to have 
lower motility, invasiveness and ability to kill bacteria due to defects in energy generation (CRAMER 
et al. 2003). Overexpression of HIF-1α also can increase the ability of phagocytic cells to kill the 
bacteria Staphylococcus aureus (ZINKERNAGEL et al. 2008).  
Overexpression of HIF can be beneficial to patients with wounds, ischemia, stroke, or 
myocardial infarction through inducing angiogenesis and protecting cells from hypoxia injury. For 
example, gene therapy with constitutive active HIF-1α transgene was found to be efficient in 
treatment of critical limb ischemia (RAJAGOPALAN et al. 2007). Similarly, ischemia preconditioning 
has been shown to reduce myocardial infarction from ischemic injury through HIF-1 dependent 
mechanisms (ECKLE et al. 2008). Pharmacological molecules that can stabilize HIFα hold great 
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therapeutic potential for treating myocardial infarction, stroke, and other hypoxia related diseases 
(MYLLYHARJU 2009) 
Tumor cells are also protected by HIF. HIF-1α overexpression has been found in many tumors. 
For example, Zhong et al. found of that among nineteen common human tumors, thirteen 
overexpressed HIF-1α, including tumors from the colon, breast, stomach, lung, skin, ovary, pancreas, 
prostate, and kidney (ZHONG et al. 1999). In tumors, overexpression of HIF-1α is detrimental, and is 
often associated with metastasis and poor prognosis (RASHEED et al. 2009; RUAN et al. 2009).  
HIF-1 inhibitors have been shown to improve the efficiency of cancer therapy (HARADA et al. 2009; 
PALAYOOR et al. 2008). 
 
The regulation of HIFα: HIFα is precisely controlled at multiple levels, and the oxygen dependent 
regulation of HIFα stability is well studied. Under normoxic condition, HIFα prolines at the LXXLAP 
motifs in N-ODDD or C-ODDD domains are hydroxylated. The hydroxylation is catalyzed by Proline 
Hydoxylase Domain proteins (PHD, also called HPH or EGLN), which belong to a family of Fe (II) 
and 2-oxoglutarate dependent dioxygenases (ARAVIND and KOONIN 2001). Once HIFα is 
hydroxylated, it will bind to the recognition subunit of a ubiquitin E3 ligase pVHL (protein von 
Hipple Lindau). This binding promotes HIFα ubiquitination and subsequent degradation (BRUICK and 
MCKNIGHT 2001; EPSTEIN et al. 2001; JAAKKOLA et al. 2001). The regulation of HIFαstability by 
PHD/VHL pathway is conserved in an array of organisms from C. elegans to humans (Epstein et al. 
2001).  
HIF-1α stability is also regulated by other posttranslational modifications or prolyl 
hydroxylation-independent mechanisms (ANDRE and PEREIRA 2008; BAE et al. 2004; 
CARBIA-NAGASHIMA et al. 2007; JEONG et al. 2002; LI et al. 2007).  
SUMOylation is a modification similar to ubiquitination. Instead of attaching ubiquitin molecules 
to lysine, SUMOylation joins small ubiquitin-like molecules to lysine. Different effects of this 
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modification on HIFα were reported in different cell types. Overexpression of SUMO-1 in HeLa cells 
or HEK293T cell line stabilized HIF-1α through SUMOylation at Lys391 and Lys477 (BAE et al. 
2004). RSUME (RWD-containing SUMOylation enhancer), induced by hypoxia, was found to 
promote HIF-1α stabilization in COS-7 cell line (CARBIA-NAGASHIMA et al. 2007). On the other 
hand, Cheng found SUMOylation of HIF-1α promoted its degradation in MEF cells or in mice 
(CHENG et al. 2007). Similarly, SUMOylation of HIF-2α was reported to promote its degradation in 
HeLa cell line (VAN HAGEN et al. 2009).  
Acetylation of HIF-1α by ARD1 (arrested defective 1) was reported to promote destabilization of 
HIF-1α mediated by pVHL pathway in mice (JEONG et al. 2002); however, human ARD1 does not 
acetylate HIF-1α (ARNESEN et al. 2005; KIM et al. 2006; MURRAY-RUST et al. 2006). Although it is 
not clear which acetylase is responsible for HIFα acetylation, it has been clearly shown that several 
HDACs, including HDAC4, HDAC6, and SIRT1, deacetylate HIF-1α and HIF-2α and activate 
expression of downstream targets in both cell culture and in mice (DIOUM et al. 2009; ELLIS et al. 
2009; KIM et al.; QIAN et al. 2006).   
In addition to stability, HIF transcriptional activity is also tightly controlled by cofactors or 
post-translational modification. HIF-1α and HIF-2α have two transactivation domains at the 
C-terminus, N-TAD and C-TAD. The association of TADs with other cofactors such as CBP/P300 or 
SRC-1 is required for HIF activity (ARANY et al. 1996; CARRERO et al. 2000; EMA et al. 1999). 
Ectopic expression of P300 enhances induction of HIF-1 target genes VEGF and EPO by hypoxia, 
and the induction is inhibited by P300/CBP inhibitors, P300 interacting protein p35srj or P53 in 
Hep3B cell line or breast cancer cells (ARANY et al. 1996; BHATTACHARYA et al. 1999; VLEUGEL et 
al. 2006).  
FIH (Factor inhibiting HIF) is another Fe (II), 2-oxoglutarate-dependent hydroxylase. Similar to 
PHDs, when oxygen concentration is high, FIH uses oxygen as a co-substrate to hydroxylate HIFα at 
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a specific asparagine residue. The hydroxylation blocks the interaction between HIF-1α and its 
coactivator CBP/P300 thereby inactivating HIF-1 (HEWITSON et al. 2002; LANDO et al. 2002).  
HIFα transcriptional activity was also found to be negatively regulated by SUMOylation. HIF-1α 
was reported to be SUMOylated and inactivated probably by RanBP2/Nup538 SUMO E3 ligase in 
HeLa cells (BERTA et al. 2007).  Similarly, HIF-2α activity was suppressed by SUMOylation at 
K394 and K497 residues in HeLa cell line (VAN HAGEN et al. 2009). De-SUMOylation of P300 by 
SENP3 was recently found to activate HIF-1 activity in mild oxidative stress (HUANG et al. 2009).  
Phosphorylation at Ser641 and Ser643 by MAPK p42/44 was shown to increase HIF-1α 
transcriptional activity, probably through blocking its nuclear exportation (MYLONIS et al. 2008; 
MYLONIS et al. 2006; RICHARD et al. 1999).  
HIFα subunits are also regulated at transcriptional or translational levels (ALAM et al. 2009; 
FUKUDA et al. 2002; GORLACH 2009). HIF-1α mRNA is upregulated in microglial cells, monocytes, 
macrophages, liver and brain in animals by transcription factor SP1 or NFγB upon hypoxia or LPS 
stimulation (FREDE et al. 2006; OH et al. 2008; RIUS et al. 2008). HIF-lα is also regulated at 
translational levels by hypoxia or growth factors such as FSH, (follicle stimulating hormone) and IGF 
(insulin-like growth factor) in a variety of cell types, mediated by the PI3K/AKT/mTOR pathway 
(ALAM et al. 2004; ALAM et al. 2009; FUKUDA et al. 2002; HUDSON et al. 2002). 
 
Prolyl hydroxylase domain containing proteins in mammals 
A group of Fe (II), 2-oxoglutarate-dependent prolyl hydroxylase domain proteins (PHD) is well 
known for their functions in the regulation of HIFα stability (SIDDIQ et al. 2007). When oxygen is 
abundant, using oxygen, 2-oxoglutarate as co-substrates, ascorbate and Fe(II) as co-factors,  PHDs 
catalyze the hydroxylation reaction at specific prolines in the LXXLAP motifs in HIFα (SIDDIQ et al. 
2007). This reaction also produces a succinate and a carbon dioxide molecule as byproducts (SIDDIQ 
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et al. 2007). The hydroxylated HIFα is then ubiquitinated and degraded by 26S proteasome (BRUICK 
and MCKNIGHT 2001; EPSTEIN et al. 2001; JAAKKOLA et al. 2001).  
The catalytic domain of PHD proteins has an eight-β-strand jelly roll structure (EPSTEIN et al. 
2001; MCDONOUGH et al. 2006). Two histidines and one aspartic acid in the catalytic core are 
required for Fe (II) binding and are critical for hydroxylase activity (EPSTEIN et al. 2001; 
MCDONOUGH et al. 2006). Thus far three PHD genes have been identified in mammals, termed 
PHD1, PHD2, and PHD3 (also named EGLN2, EGLN1 and EGLN3, or HPH3, HPH2, and HPH1) 
(BRUICK and MCKNIGHT 2001; EPSTEIN et al. 2001; TAYLOR 2001).  While functional prolyl 
hydroxylase domains are present in all PHDs (BRUICK and MCKNIGHT 2001; EPSTEIN et al. 2001; 
TAYLOR 2001), the conserved MYND (Myeloid translocation protein 8, Nervy, and DEAF1) zinc 
finger domain at the N-terminus only appears in PHD2 (ARAVIND and KOONIN 2001; TAYLOR 2001). 
The MYND domain was reported to have a negative effect on its hydroxylase activity in HeLa cells 
and in a cell-free system as assayed by adding zinc chelator TPEN or deleting the MYND domain 
(CHOI et al. 2005).  
PHD1, PHD2 and PHD3 are functionally non-redundant because they are expressed in 
tissue-specific manners, and their sub-cellular localization patterns are different as well (table 1). 
Additionally, their preferred targets are different and condition-dependent (APPELHOFF et al. 2004; 
BERRA et al. 2003; VILLAR et al. 2007). For example, using target-specific RNAi, Berra et al. found 
that PHD2 was the most important PHD that sensed oxygen changes under normoxia by regulating 
HIF-1α in all cell lines that were tested, including HeLa cells, CAL27, CAL51, HaCAT, HT29, WM9 
(BERRA et al. 2003). This is probably due to the fact that PHD2 is the most abundant PHD protein in 
normoxia in most cell lines (APPELHOFF et al. 2004). In the estrogen stimulated condition, however, 
PHD1 is induced and had remarkable roles in regulating HIF-1α (APPELHOFF et al. 2004). PHD1 and 
PHD3 prefer to hydroxylate HIF-2α rather than HIF-1α in normoxic MCF7 cells (APPELHOFF et al. 
2004). The most convincing evidence for non-redundant PHDs is from studies that show PHD2 
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knockout mice are embryonic lethal, while PHD1 and PHD3 knockout mice survive to full term with 
a variety of defects at later stages (ARAGONES et al. 2008; BISHOP et al. 2008; MINAMISHIMA et al. 
2008; TAKEDA et al. 2006). 
 
The regulation of PHDs: PHDs are regulated at multiple levels (Figure 2A). The PHD hydroxylases 
have been termed oxygen sensors because they can sense the availability of dioxygen molecules and 
translate it into transcriptional signals through HIF transcription factors (FANDREY and GASSMANN 
2009; KAELIN and RATCLIFFE 2008; LUUKKAA et al. 2009).  PHDs activity is also controlled by the 
availability of other molecules required for the reaction: Fe (II), 2-oxoglutarate and ascorbate 
(KOIVUNEN et al. 2007; SELAK et al. 2005). Additionally, citric acid cycle intermediates such as 
fumarate or succinate inhibit PHDs hydroxylation activity, probably through competing with the 
co-substrate 2-oxoglutarate for binding PHD (KOIVUNEN et al. 2007). Reactive oxygen species (ROS) 
inhibits PHDs enzymatic activity, probably by converting Fe (II) to Fe (III) (GUZY and SCHUMACKER 
2006). Taken together, PHDs can be considered as sensors of oxygen, ROS, Fe (II) and metabolic 
intermediates (Figure 3A).  
Protein-protein interaction also impacts the catalytic activity of PHDs. For example, MAPK 
(mitogen activated protein kinase) organizer 1 (MORG1), a WD (triptophan aspartate)-domain 
repeated protein, interacted with PHD3, as assayed by yeast two-hybrid and CoIP. The interaction 
probably promotes PHD3 catalytic activity (HOPFER et al. 2006). Melanoma antigen-11 (MAGE-11) 
interacted with PHD2 as assayed by yeast two-hybrid, pull-down and CoIP assay in HeLa cells, K293 
cells and Hep3B cell line (APRELIKOVA et al. 2009). This interaction inhibits PHD2 catalytic activity 
and therefore stabilized HIF-1α (APRELIKOVA et al. 2009). The fact that the catalytic activity of 
PHDs are regulated by a variety of molecules provides a promising opportunity in therapeutic 
applications (SIDDIQ et al. 2007). For example, removing superoxide with spin traps 
(A-4-pyridyl-1-oxide-N-tert- butylnitrone and 5, 5-dimethyl- 1-pyrroline N-oxide), the scavenger 
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Tempol or an SOD mimic (AEOL10113) resulted in decreasing HIF-1α protein in MCF-7 cell line 
(KAEWPILA et al. 2008). 
Two recent studies have found that PHD2 also regulates HIF-1α transcriptional activity in 
addition to its stability in mammalian cell culture (OZER et al. 2005; TO and HUANG 2005).  In 
Hep3B or U2 OS cells, overexpression of PHD2 suppresses the activity of HIF-1α N-TAD, but not 
the C-TAD in hypoxic condition; and the suppression is dependent on the presence of the conserved 
hydroxylation target proline 564. This result is confirmed in VHL-deficient C2 cell line (TO and 
HUANG 2005). Additionally, knockdown of PHD2, but not PHD1, PHD3 or VHL-1, by RNA 
interference, induces the expression of HIF-1 targets under hypoxia or in a VHL-deficient cell line 
(TO and HUANG 2005). Molecular mechanisms underlying the suppression of HIF-1 activity by 
PHD2 remain to be determined.  
PHD2 and PHD3 are transcriptionally regulated by hypoxia as HIF direct targets, and this 
regulation is also evolutionary conserved (APPELHOFF et al. 2004; BERRA et al. 2003; EPSTEIN et al. 
2001; PESCADOR et al. 2005; SHEN et al. 2005). PHD2 was also found to be transcriptionally 
repressed by TGFβ through the Smad pathway in HepG2 and fibrosarcoma HT1080, as assayed by 
Smad-specific inhibitors (MCMAHON et al. 2006). 
The protein stability of PHD1/PHD3 is also regulated by hypoxia mediated by SIAH 
(Drosophila Seven In Absentia Homolog) E3 ubiquitin ligase (NAKAYAMA et al. 2004). Ronai’s 
group found that SIAH2 was induced and associated with PHD1 and PHD3 under hypoxia in 293T 
cells (NAKAYAMA et al. 2004). Consistently, knockout Siah2 led to stabilizing PHD3 protein in both 
hypoxia and normoxia in MEF cells (NAKAYAMA et al. 2004). 
 
HIF- independent function of PHDs:In addition to regulating HIFα, PHDs have been found to 
regulate targets such as IκB kinase β and RNA polymerase II large subunit through the prolyl 
hydroxylation activity (CUMMINS et al. 2006; FU and TAUBMAN 2010 ; MIKHAYLOVA et al. 2008; 
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TAKEDA et al. 2009). The transcription factor NFκB is activated upon hypoxia. Cummins et al. found 
that inactivation of PHD1 or PHD2 by RNAi or hydroxlyase inhibitor DMOG resulted in activation 
of NFκB, and overexpression of PHD1 led to inactivation of NFκB in HeLa cell line (CUMMINS et al. 
2006). Further studies found that IκB kinase β, an NFκB positive regulator, was regulated by PHD1 
and PHD2 through prolyl hydroxylation at the LXXLAP motif, and the site-directed mutation of 
candidate proline 191 to alanine blocked the hypoxia activation of NFκB (CUMMINS et al. 2006). The 
negative regulation effect of PHD1/PHD2 on NFκB was also reported by Takeda et al. in 
macrophages (TAKEDA et al. 2009). PHD3 probably has a similar function in skeletal myoblasts (FU 
and TAUBMAN 2010). In RCC (renal cell carcinoma) cells, PHD1 was found to be associated with 
RNA polymerase II large subunit and P1465 at LXXLAP motif was identified as the PHD1 
hydroxylation target (MIKHAYLOVA et al. 2008). The P1465 hydroxylation was associated with 
non-degradation ubiquitination mediated by pVHL (MIKHAYLOVA et al. 2008). PHD1 was found to 
be required for induction of Cyclin D1 by estrogen (ZHANG et al. 2009a). This function was probably 
through hydroxylation of the target since its catalytic activity was required (ZHANG et al. 2009a).  
 
Factor inhibiting HIF (FIH) 
Although HIFα subunits are evolutionally conserved among metazoan across phyla, some 
regulation of HIF differs from species to species. For example, FIH (factor inhibiting HIF) 
hydroxylates an asparagine residue at HIFα C-terminus when oxygen level is sufficient. This 
hydroxylation prevents cofactor CBP/P300 from binding to HIFα, and therefore suppresses HIF 
activity (HEWITSON et al. 2002; LANDO et al. 2002). FIH is present in many taxa cross a large 
phylogenic distance such as mammals, beetles and corals, but there is no clear FIH homolog in 
Drosophila or C. elegans (HAMPTON-SMITH and PEET 2009). This raises an interesting question: how 
does Drosophila or C. elegans repress HIF activity? Studying the regulation of HIF in diverse models 
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will not only help to develop hypotheses about HIF regulation in general, but also shed light on 
evolutionary differences.  
 
Hypoxia responses in a genetic model organism C. elegans 
The nematode C. elegans is an excellent model system for the study of oxygen signaling for 
many reasons. First, C. elegans is a wonderful genetic model organism. It is very easy to do 
mutagenesis screens and RNAi screens (BRENNER 1974; JORGENSEN and MANGO 2002; KAMATH 
and AHRINGER 2003), and it is also convenient to screen for the phenotype of interest using the 
available mutants since C. elegans stock centers have collected a large number of them 
(www.wormbase.org).  Secondly, it has a broad oxygen tolerance; C. elegans can survive for 24 
hours under anoxia at 20-23℃, and live in 100% oxygen condition without any obvious defect for 
more than 50 generations (VAN VOORHIES and WARD 2000). Thirdly and the most importantly, many 
genes/pathways in hypoxia responses are evolutionally conserved from C. elegans to mammals. For 
example, HIF genes and pathways of regulating HIFα stability and activity are largely conserved 
from C. elegans to mammals (EPSTEIN et al. 2001; JIANG et al. 2001; POWELL-COFFMAN et al. 1998; 
SHEN et al. 2006; TO and HUANG 2005). 
Responses of C. elegans to oxygen deprivation depend on oxygen cencentration and temperature 
(POWELL-COFFMAN 2010). First, wildtype animals can survive mild oxygen deprivation (0.5-1%) at 
20-22°C, which is hif-1-dependent (JIANG et al. 2001; PADILLA et al. 2002). Secondly, under anoxia 
at 20-22°C, C. elegans can survive for up to 24 hours by entering a state called “suspended 
animation”, in which animals stop all microscopically detectable activity (PADILLA et al. 2002). This 
is independent of hif-1 (PADILLA et al. 2002).  san-1 (suspended animation), a gene encoding a 
spindle checkpoint protein, is required for C. elegans to enter suspended animation (NYSTUL et al. 
2003). Thirdly, C. elegans cannot survive <0.3% oxygen at high temperature (>26.5°C) for more than 
20 hours, or anoxia for more than 24 hours (ANDERSON et al. 2009; MABON et al. 2009; 
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MENDENHALL et al. 2009; PADILLA et al. 2002; SCOTT et al. 2002). Reduction of function (rf) 
mutations of insulin-like growth factor receptor daf-2 have been shown resistant to this extreme 
oxygen deprivation (SCOTT et al. 2002). Upon ligand binding, DAF-2 activates PI3K AGE-1, which 
in turn activates protein kinase B family proteins AKT-1/AKT-2. The activated AKT-1/AKT-2 will 
then phosphorylate FOXO transcription factor DAF-16. Phosphorylated DAF-16 can’t enter the 
nucleus and therefore is inactive. In a daf-2(rf) mutant, DAF-16 can’t be phosphorylated and 
therefore is activated. Therefore, they are resistant to many stresses and live longer (HONDA and 
HONDA 1999; KENYON et al. 1993).  daf-16(rf) mutants totally suppress the resistance to 
high-temperature oxygen deprivation in daf-2 mutants (SCOTT et al. 2002). Two daf-16 targets, 
gpd-2/gpd-3, were shown to be required for daf-2 resistance to long-term anoxia (MENDENHALL et al. 
2006). Mutations or FUdR treatment that interrupts C. elegans oocyte maturation or ovulation was 
shown to confer to its long-term anoxia survival (MENDENHALL et al. 2009). Recently, hyl-2, a gene 
that encodes ceramide synthase, was found to protect C. elegans from anoxia in daf-2 -independent 
manners (MENUZ et al. 2009).  
 
C. elegans adaptation to mild oxygen deprivation: As seen in mammals, C. elegans also has both 
acute and chronic responses to oxygen deprivation (figure 1B). Lacking a vascular system, C. elegans 
cells receive oxygen simply by diffusion. The acute responses guide C. elegans to move to an 
environment where the oxygen concentration is appropriate (5-12%) when there is no food. In the 
present of food, C. elegans does not respond to the oxygen concentrations. These responses are 
mediated by URX, AQR and PQR chemosensory neurons, which function similarly to mammalian 
sensory cells in the carotid body (CHEUNG et al. 2005; GRAY et al. 2004). A subset of soluble 
guanylate cyclases (GCY-32, GCY-34, GCY-35, GCY-36) act as oxygen receptors in those neurons. 
When ambient oxygen level is low, these sGCs form heterodimers (GCY-35/GCY-36, GCY-32/?, 
GCY-34/?) and generate cGMP, which subsequently activate cGMP gated channel and leads to 
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depolarization of cell membranes. Upon binding to oxygen, these sGCs are inactivated (CHEUNG et al. 
2005; GRAY et al. 2004). However, it is unknown how the airotaxis is connected with neuron 
membrane depolarization. EGL-9/HIF-1 was recently found to be involved in this pathway by 
altering neural circuits (CHANG and BARGMANN 2008).  
The adaptation to chronic hypoxia requires gene expression changes. Similar to that in mammals, 
a hypoxia induced factor (HIF-1) is required for most of those transcriptional changes in C. elegans 
(JIANG et al. 2001; SHEN et al. 2005). The C. elegans genome has only a single copy of mammalian 
homolog Hifα and Hifβ, which are hif-1 and aha-1 (JIANG et al. 2001; POWELL-COFFMAN et al. 1998). 
In addition to sequence similarity, several pieces of evidence indicate C. elegans hif-1 is the ortholog 
of mammalian Hifα. First, although C. elegans hif-1 is dispensable in normoxia, it is required for C. 
elegans embryos surviving mild hypoxic conditions (0.5%-1% oxygen). Secondly, in vitro expressed 
HIF-1 and AHA-1 can form a complex as assayed by coimmunoprecipitation. Thirdly, HIF-1::GFP is 
induced by hypoxia and degraded by re-oxygenating. Fourthly, HIF-1 and AHA-1 are expressed in 
most tissue cells (JIANG et al. 2001). Fifth, the protein stability of HIF-1 is regulated by EGL-9 prolyl 
hydroxylase and VHL-1 E3 ubiquitin ligase, which is evolutionally conserved (Figure 2B) (EPSTEIN 
et al. 2001). The fact that hif-1 is evolutionally conserved and nonessential in normal culture 
conditions makes C. elegans an excellent system for studying hif-1 functions and regulations. 
In order to identify genes induced by hypoxia in C. elegans, Shen et al. conducted a 
genome-wide microarray analysis (SHEN et al. 2005). To determine hif-1-dependent hypoxia induced 
genes, a strain carrying hif-1 deletion mutation was included. One hundred and ten genes were found 
to have altered their expression level more than two-fold in response to hypoxia (0.1% oxygen for 
four hours). Sixty-three of them are mediated by hif-1, since the different expression of these genes is 
not seen in the hif-1 mutant. The majority of these changes are upregulated. Only six hif-1-mediated 
and three hif-1-independent genes are downregulated. The genes that are induced by hypoxia encode 
metabolic enzymes, signaling proteins, extracellular matrix proteins, RNA and protein processing 
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components, HIF-1 hydroxylase EGL-9, dauer formation suppressor NCR-1 and CAM-1, and 
heat-shock proteins  (SHEN et al. 2005). Several hif-1 regulated genes were shown to be critical for 
C. elegans surviving hypoxia. One example is phy-2, a gene encoding prolyl hydroxylase involved in 
collagen synthesis. phy-2 inactivation by RNAi or mutation decreased the viability of embryo in 
hypoxia (SHEN et al. 2005). 
 
Regulation of HIF-1 in C. elegans: The regulation of C. elegans HIF-1 stability by EGL-9/VHL-1 is 
well characterized and evolutionally conserved (Figure 2B) (BRUICK and MCKNIGHT 2001; EPSTEIN 
et al. 2001; JAAKKOLA et al. 2001). However, little is known about the regulation of HIF-1 
transcriptional activity. Mammalian HIFα activity is controlled by another Fe(II) 2-oxogluterate 
dependent hydroxylase FIH (HEWITSON et al. 2002; LANDO et al. 2002). However, no FIH ortholog 
has not been identified in C. elegans so far (HAMPTON-SMITH and PEET 2009).  There are multiple 
hif-1 splicing isoforms in C. elegans. Two major isoforms are different by two amino acids in length. 
It remains to be determined what roles these two amino acids play.  
In addition to regulating HIF-1 stability, Shen et al. found that EGL-9 also had functions that 
suppressed expression of hif-1 target genes through a vhl-1-independent manner (Figure 3) (SHEN et 
al. 2006). The supporting data is that the HIF-1 protein levels were similar in vhl-1 and egl-9 mutant, 
while expression of hif-1 target GFP reporter and endogenous hif-1 targets is much higher in egl-9 
mutant than that in vhl-1 mutant (SHEN et al. 2006). This is also observed by studies from another 
group (BISHOP et al. 2004). 
Through forward mutagenesis screen as well as reverse RNAi screen, Shen et al. identified rhy-1 
as a negative regulator of hypoxia inducible factor (SHEN et al. 2006). rhy-1 is a hif-1 target gene that 
encodes a predicted multiple transmembrane acetyltrancferase-3 protein. A loss of function mutation 
of rhy-1 caused only a two-fold protein increase, compared to a four- to five-fold increase in vhl-1 
mutant. However, expression of hif-1 targets is much higher in rhy-1 mutant than in vhl-1 mutation. 
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Interestingly, animals carrying rhy-1 loss-of-function mutants and egl-9 loss-of-function mutants 
share some similar phenotypes. For example, both mutants reduce brood size and show the 
hif-1-dependent egg-laying defects (SHEN et al. 2006).  The additive effect of expression of hif-1 
target genes in vhl-1 rhy-1 double mutant indicates rhy-1 and vhl-1 regulate hif-1 through different 
pathways. On the other hand, rhy-1 mutation did not further increase the expression of hif-1 targets in 
egl-9 mutant animals. This genetic data suggests that rhy-1 and egl-9 may regulate hif-1 in the same 
pathway (Figure 3) (SHEN et al. 2006); however, the molecular mechanisms remain to be determined.  
 
Roles of EGL-9/HIF-1 in C. elegans development and behavior: egl-9 was first identified from a 
mutagenesis screen for egg-laying defect phenotype in C. elegans (TRENT et al. 1983). Although 
detailed mechanisms underlying the egg-laying defect of egl-9 have not been determined, it is 
mediated by hif-1 (GORT et al. 2008; SHEN et al. 2006). 
Similar to what is found in mammals, oxygen is also critical for neural development and function 
in C. elegans (CHANG and BARGMANN 2008; PANCHISION 2009; POCOCK and HOBERT 2008; SIDDIQ 
et al. 2007). When HIF-1 is stabilized by hypoxia or vhl-1 mutation, C elegans shows specific axon 
path finding and neuronal migration defects (POCOCK and HOBERT 2008). Further experiments 
identified that overexpression of a hif-1 target ephrin receptor vab-1 was critical for these defects 
(POCOCK and HOBERT 2008). In another study, Chang et al. found that overexpression of HIF-1 in 
neurons and gonadal endocrine cells (uv1 cells) by hypoxia or mutation of egl-9 would alter C. 
elegans oxygen preference to lower concentrations, through resetting neural circuits (CHANG and 
BARGMANN 2008). 
 
Roles of EGL-9/HIF-1 in C. elegans stress responses/adaptations: In addition to hypoxia, EGL-9 and 
HIF-1 play roles in resistance to heat stress, oxidative stress, polyglutamine/beta-amyloid toxicity and 
hydrogen sulfide (BELLIER et al. 2009; BUDDE and ROTH 2010; DARBY et al. 1999; MEHTA et al. 
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2009; TREININ et al. 2003; ZHANG et al. 2009b).  Wildtype C. elegans maintained at 25°C for 
eighteen hours show more resistance to heat stress at 35°C than those maintained at 20°C. This is 
called heat acclimation (AC). Treinin et al. found that hif-1 was required for AC, and animals that 
overexpressed HIF-1 by vhl-1 or egl-9 mutation were more tolerant to heat stress (TREININ et al. 
2003). Our group also found that stabilization of HIF-1 by egl-9 mutation or expressing transgene 
hif-1(P621G) increases both heat and oxidative stress resistance. HIF-1(P621G) has a point mutation 
at the EGL-9 hydroxylating target residue, therefore it is protected from hydroxylation and 
degradation by EGL-9/VHL-1 (ZHANG et al. 2009b). Interestingly, animals with hif-1 loss of function 
mutation are also resistant to heat stress and oxidative stress (BELLIER et al. 2009; ZHANG et al. 
2009b). Mehta et al. found that knocking down vhl-1 or egl-9 by RNAi protected C. elegans against 
polyglutamine/ beta-amyloid toxicity (MEHTA et al. 2009). 
 
The role of EGL-9 in pathogen resistance: Recently, C. elegans has been developed as a powerful 
genetic system to study innate immunity and resistance to bacterial pathogens (ABALLAY and 
AUSUBEL 2002; ALEGADO et al. 2003; EWBANK 2003; KURZ and EWBANK 2000; MYLONAKIS et al. 
2003; TAN 2002). Many C. elegans pathogen resistance genes are evolutionarily conserved (KIM and 
AUSUBEL 2005; NICHOLAS and HODGKIN 2004; SCHULENBURG et al. 2004). Pseudomonas 
aerugenosa is a common pathogen that can live in many environments such as water, soil, plants or 
animals. P. aerugenosa can kill C. elegans through three different mechanisms, depending on the 
bacterial strain and growth media (ABALLAY and AUSUBEL 2002; DARBY et al. 1999; TAN et al. 
1999). First, PA14 can kill C. elegans within 2-3 days if the bacteria are grown on nematode growth 
media (NGM) plates; secondly, PA14 growing on rich and high-osmolarity media kills C. elegans 
within hours (TAN et al. 1999); thirdly P. earugenosa strain PAO1 that is cultured on brain heart 
infusion medium kills C. elegans as quickly as two hours (DARBY et al. 1999). The fast killing by 
PAO1 and PA14 are also different for at least two reasons. First, fast killing by PA14 is mediated by 
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phenazines, while fast killing by PAO1 is mediated by cyanide (GALLAGHER and MANOIL 2001; 
MAHAJAN-MIKLOS et al. 1999). Secondly, the PA14 bacteria strain does not produce egl-9- 
dependent paralysis as PAO1 does (DARBY et al. 1999).  
Animals with loss of function egl-9 mutation have been shown to be resistant to P. aeruginosa 
PAO1 fast killing (DARBY et al. 1999). The PAO1 fast killing is through generation of hydrogen 
cyanide, because a hydrogen cyanide synthase mutant bacteria MP507 does not have the fast killing 
effect (GALLAGHER and MANOIL 2001). Additionally, Gallagher and Manoil showed that egl-9 
defective C. elegans were able to survive cyanide exposure that was lethal to wildtype animals. 
Interestingly, Budde and Roth recently reported that C. elegans carrying vhl-1 or egl-9 mutations was 
resistant to hydrogen sulfide (BUDDE and ROTH 2010). Both hydrogen cyanide and hydrogen 
sulfide are cytochrome c oxidase inhibitors (COOPER and BROWN 2008).  The resistance to 
hydrogen sulfide depends on hif-1 (BUDDE and ROTH 2010). egl-9 mutants were also found to be 
resistant to PFTs (pore-forming toxins) Cry21A and Cry5B from Bacillus thuringiensis (BELLIER et 
al. 2009). Pore-forming toxins are secreted by many bacterial pathogens and cause cell membranes to 
form holes (PARKER and FEIL 2005). The pore-forming toxin resistance of egl-9 mutants is also 
mediated by hif-1 (BELLIER et al. 2009). In the same study, egl-9 mutant animals is found to be 
resistant to P. aeruginosa PA14 slow killing; however, the resistance to PA14 slowing killing is 
hif-1-independent (BELLIER et al. 2009). PA14 and PFT resistances are regulated by the 
evolutionarily conserved p38 MAPK pathway and insulin-like receptor daf-2/daf-16 pathway 
(ABALLAY and AUSUBEL 2002; CHEN et al.2010; EVANS et al. 2008; HUFFMAN et al. 2004; KIM and 
AUSUBEL 2005); but the responses to P. aeruginosa fast killing in C. elegans are still poorly 
understood.  
 
Roles of HIF-1 in C. elegans lifespan extension: Recently, three independent groups reported that 
hif-1 had roles in C. elegans lifespan extension (CHEN et al. 2009; MEHTA et al. 2009; ZHANG et al. 
     19
2009b). Overexpression of hif-1 by introducing extra copies of wildtype hif-1 or stabilized 
hif-1(P621G) increases C. elegans lifespan by up to 33% (ZHANG et al. 2009b). More interestingly, 
the degree of lifespan extension is positively correlated with the HIF-1 protein level (ZHANG et al. 
2009b). Similarly, C. elegans with stabilized HIF-1 by mutations in vhl-1, or RNAi against vhl-1 or 
egl-9, also live longer (MEHTA et al. 2009). C. elegans lives longer on dietary restriction media or 
activating FOXO DAF-16 by mutations of daf-2 insulin-like receptor (KENYON et al. 1993). The 
lifespan extension by hif-1 gain of function appears to be independent of the well-known dietary 
restriction pathway and the insulin-like receptor daf-2/daf-16 pathway (MEHTA et al. 2009; ZHANG et 
al. 2009b). Surprisingly, animals with hif-1 loss of function by mutation or RNAi also live longer (up 
to 35%) (CHEN et al. 2009; ZHANG et al. 2009b). Although three independent groups reported the 
effects of hif-1 on C. elegans lifespan, there are three major differencesbetween those studies. First, 
two of them showed that gain of function of hif-1 increased the lifespan (MEHTA et al. 2009; ZHANG 
et al. 2009b), but Chen et al. found that activation of hif-1 by egl-9 mutant did not extend C. elegans 
lifespan on regular diet and suppressed the lifespan extension by dietary restriction (CHEN et al. 2009). 
Second, while two groups found that hif-1 loss of function extended C. elegans lifespan on regular 
diet (CHEN et al. 2009; ZHANG et al. 2009b), Mehta et al. did not detect any lifespan difference 
between wildtype and hif-1 mutant (MEHTA et al. 2009). Third, Zhang et al. did not detect lifespan 
extension of hif-1 loss of function in daf-16 mutant (ZHANG et al. 2009b); Chen et al. found hif-1 
RNAi could extend the lifespan of daf-16 mutant animals by 18% (CHEN et al. 2009). Those 
differences probably stem from the different assay conditions. Zhang et al. performed all experiments 
at 20°C using regular live E. coli OP50 without DNA synthesis inhibitors FUdR (ZHANG et al. 
2009b). Chen et al. did their experiments at 25°C using a different concentration of live OP50 with 
FUdR and antibiotics (CHEN et al. 2009). Mehta et al. assayed at 20°C and fed C. elegans UV-killed 
bacteria with FUdR and antibiotics (MEHTA et al. 2009). 
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Summary 
Oxygen is critical for most live organisms; however, physiological or pathological hypoxia is 
common during both normal development and pathological conditions. Under hypoxia, HIFs are 
activated due to suppression of proteasomal degradation of HIFα subunits. Additionally, HIF is also 
regulated by non-hypoxic factors (KOH and POWIS 2009; MILOSEVIC et al. 2009). In some cases, 
such as in normal development or some ischemia related diseases, stabilization of HIFα is beneficial, 
but for other diseases, such as tumors, overexpression of HIFs is deleterious. Studies of the regulatory 
network of HIF will help to treat hypoxia-related diseases (BERNHARDT et al. 2009; NIATSETSKAYA 
et al. 2010).  However, the pleiotropic functions of PHD/HIF and the limited understanding of the 
HIF regulatory network make it extremely hard to find efficient drugs (KOH et al.; MAZZONE et al. 
2009; POON et al. 2009). These studies are difficult to perform in mammalian systems due to the 
complexity of the system (e.g., multiple copies of each gene) and limited tools (e.g., inconvenient for 
genetics). C. elegans has recently emerged as an elegant model for the study of hypoxic response and 
the regulation and function of HIF-1 (POWELL-COFFMAN 2010). The EGL-9/HIF-1 pathway is 
evolutionarily conserved in C. elegans (EPSTEIN et al. 2001). In addition to HIF-1 stability, EGL-9 
also regulates HIF-1 transcriptional activity (SHEN et al. 2006). Using C. elegans as a model, we 
identified a novel hif-1 negative regulator gene rhy-1, which encodes a predicted transmembrane 
protein (SHEN et al. 2006). EGL-9 and HIF-1 have multiple roles in C. elegans development, 
behavior, stress and pathogen resistance, and lifespan extension. Some interesting questions remain: 
What are the molecular mechanisms underlying EGL-9 suppression of HIF-1 transcriptional activity? 
What other genes/proteins are involved in this pathway(s)? Is hif-1 required for Pseudomonas 
aeruginosa PAO1 fast killing resistance of egl-9 mutant? What other biological functions does 
EGL-9/HIF-1 have?  
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THESIS ORGANIZATION  
 
This thesis comprises four chapters. Chapter 1 is a literature review in three parts. Part I includes 
a general introduction to HIF hypoxia inducible factors, their roles in normal development and 
pathophysiology, and the regulation of HIF. Part II consists of a general introduction of HIF prolyl 
hydroxylase domain (PHD) proteins, the regulation of PHDs, and HIF-independent function of PHDs. 
Part III presents general C. elegans hypoxia responses, C. elegans response to mild hypoxia, and 
biological roles of EGL-9/HIF-1 in C. elegans. Chapter 2 is a manuscript published in Genetics 
entitled “Two distinct functions for EGL-9 in the regulation of HIF-1-mediated gene expression in 
Caenorhibditis elegans”. Co-authors include Zhiyong Shao (performed mutagenesis screen, all HIF-1 
activity, EGL-9 function analysis, and wrote the manuscript), Yi Zhang (created hif-1 transgenic 
animals), Jo Anne Powell-Coffman (mentored Zhiyong Shao and Yi Zhang and edited the 
manuscript). Chapter 3 is a manuscript submitted to PLOS pathogen entitled “C. elegans SWAN-1 
binds to EGL-9 and modulate hypoxia response and resistance to the bacterial pathogen Pseudomonas 
aeruginosa PAO1”. Co-authors include Zhiyong Shao (conducted of all hif-1 activity analysis, 
pathogen resistance analysis, Co-immunoprecipitation, and wrote the manuscript), Yi Zhang (mapped 
ia50), Qi Ye (conducted yeast two-hybrid analysis), Jenifer Saldanha (did brood size assay), and Jo 
Anne Powell-Coffman (mentored Zhiyong Shao, Yi Zhang and Qi Ye, and Jenifer Saldanha, and 
edited the manuscript). Chapter 4 is the general conclusion. 
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TABLE 1. The expression pattern and subcellular localization of mammaliam PHDs 
 Expression No 
expression 
Subcellular 
localization* 
Preferred 
target 
References 
PHD1 Testis (high) Heart, 
brain, liver,  kidney, 
low in lung 
skeletal 
muscle, 
spleen 
Nuclear HIF-2α, both 
NODD and 
CODD 
PHD2 Heart, brain, liver, 
skeleton muscle, 
kidney, lung (low) 
 Testis, 
spleen 
Mostly 
cytoplasmic 
HIF-1α, both 
NODD and 
CODD 
PHD3 Heart (high), brain, 
skeleton muscle, 
kidney,  lung (low) 
Testis, spleen
 
Evenly 
distributed 
HIF-2α, 
CODD from 
both HIFα 
(APPELHOFF 
et al. 2004; 
LIEB et al. 
2002; 
METZEN et 
al. 2003; 
VILLAR et al. 
2007) 
*: as assayed in U2OS cell line 
     32
FIGURE LEGENDS 
Figure 1.  Animals’ responses to oxygen deprivation: A. In response to hypoxia, mammals have 
acute responses (fast) and chronic responses (slow). Acute responses are mediated by a 
chemoreceptor in the carotid body. The low oxygen signals go to the central nervous system and 
generate immediate responses such as increase heart rate and respiration rate. Those responses speed 
oxygen transportation. Chronic responses involve gene expression changes and take longer. Most 
changes in gene expression are mediated by HIF transcription factors, stabilized and activated 
through inactivation hydroxylase (PHDs and FIH). Expression of HIF targets (including VEGF, 
glycolytic enzymes, Oct-4 etc.) increase oxygen transport, decrease oxygen consumption and 
determine cell fate. B. Similarly, C. elegans has both acute and chronic responses to oxygen 
deprivation. The acute responses cause animals move to an environment with appropriate oxygen 
cencentration. This is mediated by sGC (soluble guanylate cyclase) located in URX, AQR and PQR 
neurons as well as. EGL-9 has an important role in chronic responses. Hypoxia inactivates EGL-9 and 
stabilizes HIF-1. Subsequently, expression of hif-1 targets is changed to increase resistance hypoxia 
or other stresses (such as heat, oxidative, pathogen) and extend lifespan.  
 
Figure 2.  Regulations of prolyl hydroxylase domain proteins: A. PHDs are precisely controlled at 
many different levels. Transcriptionally, they are regulated by HIF transcription factors (positively) 
and transforming growth factor β (negatively). PHDs activity is regulated by many small molecules 
including O2, Fe(II), 2-OG, ROS, NO, pyruvate, succinate, etc. It is also controlled by interacting 
proteins such as MAGE11 (negatively) and MORG1 (positively). The protein stability of PHDs is 
also strictly controlled by ubiquitin E3 ligase SIAH1/2. B. C. elegans PHDs homolog EGL-9 is 
regulated at different levels. Solid lines indicate identified regulation pathways; dashed lines indicate 
predicted regulation pathways. 
Arrows indicate positive effects; “   ” indicates negative effect. 
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Figure 3.  Regulations of C. elegans HIF-1: Under normoxic conditions, HIF-1 is hydroxylated at 
Pro621 by EGL-9. The hydroxylation promotes HIF-1 ubiquitination through binding to an ubiquitin 
E3 ligase subunit VHL-1 and degradation. Under hypoxic conditions where oxygen is limited, the 
catalytic activity of EGL-9 is inhibited. HIF-1 will dimerize with AHA-1 and regulate its downstream 
targets. Two HIF-1 target genes egl-9 and rhy-1 were shown to repress HIF-1 transcriptional activity. 
It appears that egl-9 and rhy-1 act in the same pathway; however, the molecular mechanism is unclear. 
Additionally, rhy-1 also represses hif-1 expression (not shown in this figure) (SHEN et al. 2006). 
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ABSTRACT 
Oxygen is critically important to metazoan life, and the EGL-9 / PHD enzymes are key regulators of 
hypoxia (low oxygen) response.  When oxygen levels are high, the EGL-9 / PHD proteins 
hydroxylate hypoxia-inducible factor (HIF) transcription factors.  Once hydroxylated, HIF alpha 
subunits bind to von Hippel-Lindau (VHL) E3 ligases and are degraded.  Prior genetic analyses in C. 
elegans had shown that EGL-9 also acted through a vhl-1-independent pathway to inhibit HIF-1 
transcriptional activity.  Here, we characterize this novel EGL-9 function.  We employ an array of 
complementary methods to inhibit EGL-9 hydroxylase activity in vivo.  These include hypoxia, 
hydroxylase inhibitors, mutation of the proline in HIF-1 that is normally modified by EGL-9, and 
mutation of the EGL-9 catalytic core.  Remarkably, we find that each of these treatments or 
mutations eliminates oxygen-dependent degradation of HIF-1 protein, but none of them abolish 
EGL-9-mediated repression of HIF-1 transcriptional activity.  Further, analyses of new egl-9 alleles 
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2 Author for correspondence 
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reveal that the evolutionarily conserved MYND zinc finger domain does not have a major role in 
regulating HIF-1 protein stability of transcriptional activity.  We conclude that C. elegans EGL-9 is a 
bifunctional protein.  In addition to its well-established role as the oxygen sensor that regulates HIF-1 
protein levels, EGL-9 inhibits HIF-1 transcriptional activity via a pathway that has little or no 
requirement for hydroxylase activity or for the EGL-9 MYND domain.  
 
INTRODUCTION 
Cells and tissues are often deprived of oxygen during normal development and during disease.  
Examples include animals that encounter hypoxic soil or aqueous microenvironments, mammalian 
tissues that receive insufficient oxygen when the cardiovascular system is taxed or disabled, and cells 
at the center of a poorly vascularized tumor.  Most metazoans rely on aerobic respiration as a 
primary source of energy, and adaptation to hypoxia is of central importance.  The 
hypoxia-inducible factor (HIF) transcription complexes have been termed master regulators of 
hypoxia response, because they regulate most hypoxia-induced changes in gene expression in animals 
as diverse as humans and the nematode C. elegans. (KAELIN and RATCLIFFE 2008). In mammals, 
these HIF targets include genes that regulate growth, energy metabolism, cellular differentiation, 
apoptosis, inflammation, and angiogenesis (RANKIN and GIACCIA 2008; SIDDIQ et al. 2007; 
WEIDEMANN and JOHNSON 2008).  
The EGL-9 / PHD proteins act as cellular oxygen sensors, and they are at the core of HIF 
regulatory networks.  When oxygen levels are sufficiently high, PHD / EGL-9 proteins hydroxylate 
conserved proline residues in the HIF alpha subunits.  Once hydroxylated, HIF  proteins 　 bind to 
the von Hippel-Lindau tumor suppressor protein (VHL) (BRUICK and MCKNIGHT 2001; IVAN et al. 
2001; JAAKKOLA et al. 2001; MIN et al. 2002). VHL targets HIF  for polyubiquitination and 　
proteasomal degradation (MAXWELL et al. 1999; OHH et al. 2000).  
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The nematode C. elegans has provided important insights into hypoxia signaling.  The egl-9 
gene was first identified in genetic screens for mutations that disrupted egg laying (TRENT et al. 1983) 
and for mutations that conferred resistance to the bacterial pathogen Pseudomonas aeruginosa 
(DARBY et al. 1999).  Subsequent studies identified C. elegans EGL-9 as the oxygen-sensitive 
enzyme that controlled oxygen-dependent degradation of HIF-1, and EGL-9 was shown to be 
orthologous to mammalian PHD1, PHD2, and PHD3 (EPSTEIN et al. 2001). C. elegans that carry a 
deletion in hif-1 are not able to survive development in hypoxia (JIANG et al. 2001; PADILLA et al. 
2002).  hif-1 and egl-9 have been shown to have roles in other important processes, including heat 
acclimation, neural development, behavioral responses to oxygen or carbon dioxide, cyanide 
resistance, and aging (BRETSCHER et al. 2008; CHANG and BARGMANN 2008; CHEN 2009; 
GALLAGHER and MANOIL 2001; JIANG et al. 2001; MEHTA et al. 2009; MILLER and ROTH 2009; 
POCOCK and HOBERT 2008; TREININ et al. 2003; ZHANG et al. 2009).  
Genetic analyses in C. elegans have shown that EGL-9 regulates HIF-1 via two distinct 
pathways: oxygen-dependent degradation of HIF-1 and an uncharacterized vhl-1-independent 
pathway in which EGL-9 represses HIF-1 transcriptional activity (illustrated in Figure 1A).  In 
previous studies, we had discovered that the mRNA transcripts for HIF-1 target genes were expressed 
at much higher levels in egl-9 mutants, compared to vhl-1 mutants (SHEN et al. 2006).  Other studies 
had suggested that mammalian PHD proteins might also regulate HIF activity in some 
VHL-independent contexts (OZER et al. 2005; TO and HUANG 2005).  These findings supported the 
intriguing hypothesis that EGL-9/ PHD proteins had VHL-independent roles that might not involve 
HIF hydroxylation.   
In this study, we investigate the vhl-1-independent mechanism by which C. elegans EGL-9 
represses HIF-1 activity.  We find that while hydroxylation of HIF-1 at proline residue 621 by 
EGL-9 is required for HIF-1 destabilization, it is not essential for the vhl-1-independent functions of 
EGL-9.  Further, we show that the two EGL-9 pathways have differing sensitivities to mutations or 
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pharmacological treatments that impair hydroxylase activity.  Collectively, these data show that 
EGL-9 represses HIF-1 transcriptional activity via a pathway that has little or no requirement for 
EGL-9 hydroxylase activity.   
 
METHODS 
Alleles and worm culture: C. elegans were grown at 20℃ using standard methods (BRENNER 1974).  
The loss-of-function alleles, transgenes, and strains described in this study are listed in supplemental 
materials (Tables S1, S2, and S3). All new mutations and integration events were outcrossed to 
wild-type animals at least four times.  
 
Constructs and worm transformation:  The Pegl-9::egl-9::tag expression construct includes 1.6 kb 
of egl-9 5’ regulatory sequence, genomic sequence for the first three egl-9 exons, and the remaining 
exons from the cDNA for the predominant egl-9 mRNA isoform (egl-9a, illustrated in Figure S3).  
The egl-9 coding sequences are fused in frame to green fluorescent protein (GFP).  Further details of 
plasmid construction are in supplemental information. To create the Pegl-9::egl-9(H487A)::tag 
construct, the egl-9 codon for histidine 487 was changed to encode alanine. 
The Phif-1::hif-1::tag construct contains 5.2 kb of hif-1 5’ regulatory sequence, the genomic 
sequence for the first exon and first intron of hif-1, cDNA sequence for hif-1 exons 2 – 9, and an 
epitope tag.  To create the Phif-1::hif-1(P621G)::tag construct, the codon for proline 621 was 
modified to encode glycine. The hif-1 transgenes are further characterized in Figure S1 and in 
(ZHANG et al. 2009). 
The egl-9 constructs were introduced to the strain ZG305 [egl-9(sa307); unc-119(ed3)], and the 
hif-1 constructs were introduced to ZG228 [hif-1(ia04), unc-119(ed3)], by microparticle 
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bombardment with the unc-119 rescue plasmid (pPD#MMO16b) as a co-transformation marker 
(PRAITIS et al. 2001).  The resulting transgenic strains were each backcrossed at least 4 times. 
 
MOS1 mediated mutagenesis:  We generated the egl-9 loss-of-function alleles ia58, ia60, and ia61 
in a screen for Mos1 transposon-mediated mutations that dramatically increased the expression of the 
Pnhr-57::GFP reporter (SHEN et al. 2006). The methods for Mos1 mobilization have been described 
previously (GRANGER et al. 2004). We screened approximately 164,600 genomes, as diagrammed in 
Figure S4. 
 
Protein blots:  Protein blots were probed with monoclonal antibodies recognizing the following 
epitopes: GFP (antibody from Roche at 1:1000 dilution); HA (antibody from Cell Signaling 
Technology clone 6E2 at 1:1000 dilution); myc (mouse ascites, clone 9E10, from the Developmental 
Studies Hybridoma Bank at 1:1000 dilution), or AHA-1 (JIANG et al. 2001) (1:100 dilution). The 
secondary antibody (goat anti-mouse IgG+IgM from Biorad) was diluted 1:2000.  Further 
experimental and statistical methods are in supplemental information (File S1). 
 
Real time PCR:  We used Trizol reagent (Invitrogen) to isolate total RNA from developmentally 
synchronized populations of L4 or young adult stage worms. Total RNA from each sample was 
treated by RNase free DNase (Promega) and reverse transcribed to complementary DNA using 
Oligo(dT18) primers and AffinityScript reverse transcriptase (Stratagene). Quantitative RT-PCR was 
performed using the iQ SYBR GREEN supermix (Bio-Rad) real-time PCR system, and each reaction 
included cDNA from 50-100ng total RNA.  The primers for K10H10.2 and inf-1 have been 
published previously (SHEN et al. 2006).  inf-1 is not regulated by hypoxia and was used as an input 
control (SHEN et al. 2005; SHEN et al. 2006).  At least three biological replicates were analyzed for 
each experiment, and each PCR reaction was performed in duplicate.  The standard curve method 
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was used to analyze the expression levels.  Two-sample paired t-tests were used to assess statistical 
significance of differences.  
 
RESULTS 
Prior studies had shown that egl-9 inhibited HIF-1 by two genetic pathways:  (1) 
VHL-1-mediated oxygen-dependent degradation (EPSTEIN et al. 2001) and (2) repression of HIF-1 
transcriptional activity via a pathway that did not require vhl-1 (SHEN et al. 2006) (illustrated in 
Figure 1A).  While oxygen-dependent degradation is well-characterized, the mechanisms by which 
EGL-9 inhibits HIF-1 activity are not understood.  In the studies described here, we have conducted 
a series of experiments to distinguish between alternative models for how EGL-9 represses expression 
of HIF-1 targets independent of VHL-1 (pathway 2 in Figure 1A).  The simplest model was that 
EGL-9-mediated hydroxylation of HIF-1 at proline 621 resulted in both degradation of HIF-1 protein 
and inhibition of HIF-1 transcriptional activity (model a in Figure 1B).  An alternative model was 
that EGL-9 hydroxylated another region of HIF-1 or a different protein to repress HIF-1-mediated 
transcription (model b in Figure 1B).  Finally, we considered the possibility that EGL-9 inhibited 
HIF-1 transcriptional activity via a novel mechanism that did not require EGL-9 prolyl hydroxylase 
activity (model c in Figure 1B).  The experiments described herein are designed to distinguish 
between these three models. 
 
Effects of the HIF-1(P621G) mutation:  EGL-9 hydroxylates proline 621 of HIF-1 (EPSTEIN et al. 
2001).  This is the only known EGL-9 target in the HIF-1 protein, and HIF-1 transgenes that carry 
the P621G mutation are not degraded through the EGL-9/ VHL-1 pathway [(ZHANG et al. 2009); 
Figure S1C].  To determine whether the HIF-1 (P621G) mutation eliminated all regulation of HIF-1 
by EGL-9, we examined the effects of egl-9 mutations in animals expressing HIF-1(P621G).  In 
these experiments, the endogenous hif-1 gene was knocked-out, and hif-1 function was restored by an 
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integrated transgene expressing either epitope-tagged wild-type HIF-1 or stabilized HIF-1(P621G).  
To assess the effects of the mutations on HIF-1 activity, we assayed the expression of two HIF-1 
target genes: K10H10.2 and the Pnhr-57::GFP reporter (SHEN et al. 2006).  In control experiments, 
we confirmed that in animals expressing the wild-type HIF-1 transgene, a strong loss-of-function 
mutation in egl-9 resulted in dramatic over-expression of Pnhr-57::GFP (Figure 2A).  We then 
assayed the expression of HIF-1 targets in three independently isolated lines expressing 
HIF-1(P621G), and we found that the egl-9(sa307) mutation caused markedly higher expression of 
Pnhr-57::GFP in these animals (Figure 2B).  K10H10.2 mRNA levels were also significantly 
increased by the egl-9(sa307) loss-of-function mutation in animals expressing the stabilized HIF-1 
(Figure 2C).  These data demonstrated that the HIF-1(P621G) mutation did not abolish all regulation 
of HIF-1 by EGL-9, and this effectively disproved ‘model a’ as described in Figure 1B.  
 
Hypoxia or iron chelator treatments that inhibit oxygen-dependent degradation of HIF-1 do not 
eliminate all EGL-9 functions: Having established that EGL-9 had functions other than hydroxylation 
of HIF-1 proline 621, it was important to determine whether those other functions required EGL-9 
hydroxylase activity.  We reasoned that if EGL-9 hydroxylated other substrates to repress HIF-1 
activity (model b in Figure 1B), then all EGL-9 functions would be repressed by treatments that 
inhibited EGL-9 hydroxylase activity.  The HIF-1 hydroxylation reaction requires oxygen, 
2-oxoglutarate, and Fe+2 (KAELIN and RATCLIFFE 2008).  Oxygen-deprivation or the iron chelator 2, 
2’-dipyridyl (DIP) inhibit this reaction (BISHOP et al. 2004).  In control experiments, we confirmed 
that HIF-1 protein was stabilized by hypoxia (0.5% oxygen) or DIP treatments (Figure 3A).  We 
next asked whether inhibitors of EGL-9 hydroxylation activity could fully phenocopy a strong 
loss-of-function mutation in egl-9.  We found that hypoxia, DIP, or a deletion mutation in vhl-1 
increased Pnhr-57::GFP to similar levels (Figure 3B).  Although the hypoxia and DIP treatments 
prevented oxygen-dependent degradation of HIF-1, they did not increase expression of Pnhr-57::GFP 
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to the levels caused by strong loss-of-function mutations in egl-9 (compare the last bar in Figure 3B 
to the other conditions).  Hypoxia or DIP had no effect on Pnhr-57::GFP levels in vhl-1 mutant 
animals. Taken together, these data demonstrated that the vhl-1-independent functions of EGL-9 were 
relatively insensitive to inhibitors of hydroxylase activity. 
 
Mutation in the EGL-9 catalytic core has differential effects on the two EGL-9 pathways: The 
findings that hypoxia or DIP treatments did not increase expression of Pnhr-57::GFP in vhl-1 mutants 
provided support for a model in which EGL-9 had functions that did not require hydroxylase activity 
(model c in Figure 1B).  To test this hypothesis further, we analyzed the consequences of the 
EGL-9(H487A) mutation.  The histidine 487 residue is in the catalytic core of EGL-9.  This region 
of the protein contributes to the Fe(II)-binding pocket and is highly conserved (Figure 4A) 
(MCDONOUGH et al. 2006).  Mutation of the analogous residue in the mammalian PHD2 protein 
(His313) has been shown to eliminate hydroxylase activity (PAN et al. 2007).   
In order to compare the functions of wild-type EGL-9 with EGL-9(H487A), we first constructed 
and assayed an epitope-tagged wild-type egl-9 minigene, in which genomic sequence including 5’ 
regulatory sequences, three exons and two introns were fused to cDNA for the remaining exons in the 
predominant egl-9 mRNA isoform (Figure 4B).  The minigene was able to restore egl-9 function in 
an egl-9(sa307) mutant, as assayed by destabilization of HIF-1 (compare lanes 1 and 2 in Figure 4C), 
repression of Pnhr-57::GFP expression (compare bars 1 and 2 in Figure 4D), or repression of 
K10H10.2 mRNA levels (compare bars 1 and 2 in Figure 4E). We then introduced the H487A point 
mutation to the wild type egl-9 minigene and analyzed the ability of the egl-9(H487A) minigene to 
rescue egl-9(sa307). As expected, EGL-9(H487A) did not destabilize HIF-1 (lanes 3, 4 and 5 in 
Figure 4C). The iaIs38, iaEx101, and iaEx110 transgenes all expressed similar levels of EGL-9 
wild-type or mutant protein, while expression from iaEx104 was slightly lower (Figure S2). 
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Having confirmed that EGL-9(H487A) could not rescue oxygen-dependent degradation of HIF-1 
in egl-9(sa307) mutants (pathway 1 in Figure 1A), we next asked whether this catalytically deficient 
EGL-9 was able to repress expression of HIF-1 target genes (pathway 2 in Figure 1A).  To address 
this question, we compared the ability of wild-type egl-9 and egl-9(H487A) minigenes to inhibit 
expression of Pnhr-57::GFP in animals that carried a strong loss-of-function mutation in the 
endogenous egl-9 gene.  The wild-type egl-9 minigene (iaIs38) stabilized HIF-1 (see lane 2 of 
Figure 4C) and repressed Pnhr-57::GFP (compare first and second bars of Figure 4D).  Stabilization 
of HIF-1 by DIP resulted in increased Pnhr-57::GFP expression, but not to the levels seen in animals 
that lack egl-9 function (compare the third bar and the first bar in Figure 4D).  In these assays, the 
HIF-1 reporter gene was similarly regulated in animals containing the wild-type egl-9 locus or in 
animals expressing egl-9 from the iaIs38 transgene.   
Each of the three egl-9(H487A) transgenic arrays were also able to repress expression of 
Pnhr-57::GFP, although not to the level achieved by the wild-type egl-9 transgene (Figure 4D).  As 
expected, DIP had no significant effect when the EGL-9 hydroxylase domain was disabled by the 
H487A mutation (the filled bars in sets 3, 4 and 5 of Figure 4D).  These data demonstrated that 
while disruption of the EGL-9 iron-binding pocket was sufficient to abolish oxygen-dependent 
degradation of HIF-1 (Figure 4C), this mutation did not eliminate all EGL-9-mediated inhibition of 
the HIF-1 reporter (Figure 4D).  
These findings supported a model in which EGL-9 had two functions:  (i) hydroxylation of 
HIF-1 in the HIF-1 oxygen-dependent degradation pathway, and (ii) repression of HIF-1 
transcriptional activity by a pathway that had little or no requirement for EGL-9 hydroxylation 
activity.  To further compare the ability of wild-type and catalytically deficient egl-9 transgenes to 
repress expression of HIF-1 targets, we analyzed K10H10.2 mRNA by RT-PCR.  As shown in 
Figure 4E, when the wild-type egl-9 transgene was introduced to an egl-9(sa307) mutant, it reduced 
expression of K10H10.2 over 10-fold (compare first and second bars of Figure 4E) to levels similar to 
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those in wild-type animals (bar 3 in Figure 4E).  The egl-9(H487A) transgenes did not destabilize 
HIF-1 (as shown in Figure 4C), so we expected that if they retained the ability to repress HIF-1 
transcriptional activity via vhl-1-independent pathways, then the egl-9(H487A) transgenic animals 
would express K10H10.2 at levels lower than egl-9(sa307) controls and similar to the levels seen in 
vhl-1(ok161) mutants.  As shown in the last three bars of Figure 4E, K10H10.2 mRNA levels were 
significantly reduced in each of the three egl-9(H487A) lines, relative to the egl-9(sa307) control.  In 
sum, the data in Figure 4 show that the catalytically deficient EGL-9 protein was unable to destabilize 
HIF-1, but retained the ability to repress expression of HIF-1 targets.   
 
egl-9 mutations and their effects on HIF-1: We sought to understand the relationships between 
EGL-9 functions and EGL-9 structure further by characterizing a series of mutations in the 
endogenous egl-9 gene. Like its mammalian cognates, EGL-9 includes both an MYND zinc finger 
domain and a prolyl hydroxylase domain (Figure 5A).  The egl-9 locus encodes at least nine mRNA 
isoforms.  We sequenced 19 egl-9 cDNAs and have submitted these sequences to Wormbase 
(ROGERS et al. 2008).  The structures and relative frequencies of the alternatively spliced egl-9 
transcripts are diagrammed in Figure S3.  Prior chemical mutagenesis screens had isolated 
loss-of-function mutations in egl-9 that caused defects in egg laying or resistance to cyanide produced 
by the bacterial pathogen Pseudomonas aeruginosa (DARBY et al. 1999; GALLAGHER and MANOIL 
2001).  More recently, the C. elegans gene knockout consortium isolated two egl-9 deletion alleles: 
gk277 and ok478 (diagrammed in Figure 5A).  We isolated three additional loss-of-function 
mutations in egl-9 in a MOS1 transposon-mediated screen to identify mutations that caused 
over-expression of Pnhr-57::GFP.  The screen is illustrated in Figure S4, and the new egl-9 
mutations are described in Figure 5A.   
Initially, we characterized six egl-9 loss-of-function mutations.  These included a mutation 
previously shown to be a strong loss-of-function allele (sa307), the three new alleles from the 
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MOS1-mediated screen (ia58, ia60, and ia61), a deletion allele that removed exons common to all 
known egl-9 isoforms (ok478), and a mutation that had been shown to confer resistance to 
Pseudomonas aeruginosa, but did not cause egg-laying defects [sa330; (DARBY et al. 1999)].  For 
each allele, we characterized its effects on HIF-1 stability and on expression of a HIF-1 target gene, 
Pnhr-57::GFP.  When comparing the relative effects of these mutations, we used egl-9(sa307) as a 
reference allele, because prior studies had shown that egl-9(sa307) was a severe mutation that 
abolished degradation of HIF-1 through the EGL-9 / VHL-1 pathway (EPSTEIN et al. 2001; SHEN et 
al. 2006).  All six of the egl-9 mutations resulted in HIF-1 over-expression phenotypes very similar 
to that seen in egl-9(sa307), indicating that each of these alleles severely disabled oxygen-dependent 
degradation of HIF-1 (Figure 5B).   
We next asked how each of these mutations affected expression of a HIF-1 target gene. We 
found that while the Pnhr-57::GFP reporter was over-expressed in all of these strains, two of the 
alleles, ia60 and sa330, caused slightly less severe phenotypes (Figure 5C).  The ia60 allele is a 
MOS1 transposon insertion in exon 3, and the sa330 mutation causes an early translational stop in 
exon 2 of the predominant egl-9 transcript (Figure 5A) (DARBY et al. 1999).  The egg laying defects 
caused by the egl-9(ia60) or egl-9(sa330) alleles were also less severe, when compared to other egl-9 
mutations [(DARBY et al. 1999) and data not shown].  These findings suggest that the proteins 
encoded by the egl-9 ia60 and sa330 alleles cannot destabilize HIF-1, but they retain some ability to 
repress expression of HIF-1 target genes.  
 
Characterization of egl-9(gk277), an allele that deletes the MYND zinc finger domain: The 
egl-9(gk277) mutation provided a unique opportunity to investigate the role of the MYND motif in 
EGL-9 function.  This deletion allele removes most of egl-9 exon 2 and intron 2 (Figure 5A).  We 
generated cDNA from egl-9(gk277) animals and determined that in these mutants egl-9 exon 1 was 
spliced to exon 3, resulting in an in-frame deletion of the evolutionarily conserved MYND zinc finger 
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domain.  We determined that HIF-1 protein levels were 1.8-fold higher in egl-9(gk277), relative to 
animals containing the wild-type egl-9 gene, and the statistical significance of this difference is 
marginal (lanes 1 and 2 in Figure 6A).  By comparison, strong loss-of-function mutations in egl-9 or 
vhl-1 caused 3- to 4-fold increases in HIF-1 levels.  In a vhl-1(ok161) background, the egl-9(gk277) 
mutation had no effect on HIF-1 protein levels (lanes 3 and 4 in Figure 6A).  
We next investigated the effects of the gk277 mutation on the expression of two genes regulated 
by HIF-1. While the Pnhr-57::GFP reporter and the endogenous K10H10.2 gene were over-expressed 
in egl-9(sa307) animals by about 400 and 40-fold respectively, the gk277 mutation caused only 2- to 
3-fold increases in the expression of these HIF-1 targets (Figures 6B and 6C)  In animals in which 
HIF-1 was stabilized by the vhl-1(ok161) mutation, the gk277 mutation had relatively small effects on 
the expression of either gene (bars 3 and 4 in Figures 6B and 6C).  Thus, deletion of the MYND 
domain in egl-9(gk277) animals had little effect on the ability of EGL-9 to inhibit HIF-1 
transcriptional activity.  
 
DISCUSSION 
EGL-9 is the key regulator of HIF-1 protein stability and HIF-1 activity.  In C. elegans and in 
mammals, HIF induces the expression of EGL-9/PHD, and this establishes a negative feedback loop 
that attenuates HIF activity (BERRA et al. 2006; BISHOP et al. 2004; SHEN et al. 2005). The catalytic 
functions of EGL-9 / PHD enzymes are of central importance in normal development, homeostasis 
and disease states and have been studied intensively (KAELIN and RATCLIFFE 2008). In humans, 
mutations in the PHD2 active site and other mutations that stabilize HIF have been linked to familial 
erythrocytosis (AL-SHEIKH et al. 2008; MARTINI et al. 2008; PERCY et al. 2007; PERCY et al. 2006).  
Efforts are underway to develop small molecule inhibitors of PHD activity for the treatment of 
anemia and other diseases that may be mitigated by increased HIF protein stability (HEWITSON et al. 
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2004). Here, we have shown that EGL-9 has a second function: it represses HIF-1 activity through a 
pathway that has little or no requirement for EGL-9 hydroxylase activity.    
 
Hydroxylase deficient EGL-9 still represses HIF-1 activity: The evidence that C. elegans EGL-9 
regulates HIF-1 stability and HIF-1 activity through two distinct mechanisms is multi-fold:  (i) 
Loss-of-function mutations in egl-9 or vhl-1 stabilize HIF-1 protein, but mutations in egl-9 cause 
much higher levels of HIF-1 target gene expression (SHEN et al. 2006) (Figure S1B, 3A, and 3B); (ii) 
Mutation of the proline normally hydroxylated by EGL-9 [in HIF-1(P621G)] releases HIF-1 from 
oxygen-dependent degradation, but it does not prevent EGL-9-mediated inhibition of HIF-1 target 
gene expression (Figure S1C, 2B and 2C); (iii) Treatments that inhibit EGL-9 catalytic activity do not 
fully phenocopy the egl-9 phenotype, and hypoxia or DIP have little effect on HIF-1 activity in vhl-1 
mutants (BISHOP et al. 2004) (Figure 3B); and (iv) The H487A mutation in the iron-binding pocket of 
the EGL-9 catalytic domain stabilizes HIF-1, but EGL-9(H487A) still inhibits transcriptional activity 
(Figure 4C, 4D, and 4E).  
We conclude that EGL-9 is a bifunctional protein, with some functions that require hydroxylase 
activity and others that do not.  We have considered the formal possibility that the EGL-9(H487A) 
mutant protein retains some catalytic function.  However, it is clear that the mutation in the EGL-9 
iron binding pocket abrogates hydroxylase activity, as assayed by destabilization of HIF-1 (Figure 
4C).  Further, some EGL-9 functions are insensitive to inhibitors of hydroxylase activity.  In 
EGL-9(H487A) animals or in vhl-1 mutants, DIP treatments do not increase HIF-1 activity (Figure 
3B, 4D).  We conclude that the two EGL-9 pathways have dramatically different requirements for 
EGL-9 prolyl hydroxylase activity. 
It has been proposed that mammalian PHD proteins may also have functions that do not require 
hydroxylase activity.  PHD2 over-expression was shown to reduce expression of HIF targets in a 
cell line lacking VHL and in a manner independent of HIF destabilization.  Further, PHD2 exerted 
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this inhibitory effect on the HIF-1  transcriptional activation region fused to a heterologous DNA 　
binding domain (TO and HUANG 2005). These data are consistent with a model in which PHD2 could 
recruit repressors to the HIF transcriptional complex, independent of its role in VHL-mediated 
degradation of HIF.  In an independent study of hypoxia-treated HeLa cells, PHD2 was shown to be 
associated with HIF DNA binding sites.  PHD2 was also shown to bind the ING4 tumor suppressor, 
which has been proposed to act as a transcriptional repressor (OZER et al. 2005).  In a third study, 
expression of a catalytically deficient form of PHD2 was shown to inhibit endothelial cell 
proliferation (TAKEDA and FONG 2007).  Most recently, PHD2 has been shown to have functions in 
angiogenesis that do not require hydroxylase activity (CHAN et al. 2009).  These findings do not take 
away from the central importance of PHDs as oxygen sensors, but it provide strong evidence that 
mammalian PHD proteins have additional functions that do not require hydroxylase activity.   
 
Characterization of egl-9 loss-of-function alleles: Several egl-9 loss-of-function alleles have been 
isolated in screens for mutations that result in egg-laying deficiencies (TRENT et al. 1983), resistance 
to Pseudomonas aeruginosa infection (DARBY et al. 1999) or over-expression of HIF-1 target genes 
(this study).  In all cases that have been tested, depletion of hif-1 by RNAi or mutation has been 
shown to suppress egl-9 mutant phenotypes (CHANG and BARGMANN 2008; GORT et al. 2008; 
POCOCK and HOBERT 2008; SHEN et al. 2006).  We assayed several of these alleles to determine 
whether they had differential effects on HIF-1 stabilization or VHL-1-independent suppression of 
HIF-1 activity.  With the exception of the gk277 deletion of the MYND domain, all of the mutations 
impaired both pathways.  Two findings are of particular interest.  First, there is a correlation 
between the degree of Pnhr-57::GFP over-expression and the egl phenotypes caused by the egl-9 
mutations.  egl-9(sa330) and egl-9(ia60) mutants are not egg-laying defective.  Second, the 
egl-9(sa330) mutation causes a translational stop in exon 2 of the predominant egl-9 transcript 
(DARBY et al. 1999) (Fig 5C), but it does not abolish all egl-9 function.  Six of the nine egl-9 mRNA 
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isoforms do not include exon 2 or the MYND domain.  It is possible that these other transcripts 
provide some function in egl-9(sa330) mutants.   
 
The EGL-9 MYND domain: The MYND zinc finger domain is an evolutionarily conserved feature of 
PHD proteins.  Since the divergence of nematode and mammalian lineages, the PHD gene amplified 
in mammals.  The PHD1, PHD2, and PHD3 genes have diverged and have acquired different tissue 
distributions, subcellular localization patterns, and functions (FONG and TAKEDA 2008; KAELIN and 
RATCLIFFE 2008). PHD3 lacks an MYND domain, and, although it has different substrate 
specificities than PHD1 and PHD2, it can hydroxylate some substrates (EPSTEIN et al. 2001). 
Deletion of the MYND domain in PHD2 resulted in increased HIF-1 destabilization in HeLa cells 
(CHOI et al. 2005), suggesting that the MYND domain might modulate PHD activity in some contexts.  
The gk277 mutation presents a unique opportunity to examine the in vivo effects of deleting the 
MYND domain, and C. elegans egl-9(gk277) mutants had been reported to have defects in neuronal 
pathfinding (POCOCK and HOBERT 2008).  It was, therefore, of particular interest to determine 
whether the egl-9(gk277) mutation impaired one or both of the EGL-9 pathways for HIF-1 regulation.  
In our assays, the egl-9(gk277) mutation did not change total HIF-1 levels and had only marginal 
effects on the expression of HIF-1 targets.   
This study provides a foundation for further experiments to understand the mechanism by which 
EGL-9 inhibits expression of HIF-1 transcriptional targets.  We have established that mutations or 
treatments that inhibit hydroxylase activity do not eliminate all regulation of HIF-1 by EGL-9.  The 
next important steps will be to identify EGL-9 / PHD interaction partners and to characterize their 
respective roles in regulating HIF-1 stabilization or activity.   
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FIGURE LEGENDS 
 
Figure 1.  EGL-9 functions and models tested in this study:  (A) EGL-9 regulates HIF-1 by two 
pathways, and they are illustrated here.  First, EGL-9 controls oxygen-dependent degradation of 
HIF-1 (labeled pathway 1).  EGL-9 hydroxlates HIF-1 on a conserved proline residue (P621), and 
this enables binding of HIF-1 to the VHL-1 E3 ligase.  HIF-1 is then degraded.  Molecular oxygen, 
Fe(II), and 2-oxoglutarate are required for the hydroxylation reaction.  EGL-9 also suppresses 
expression of HIF-1 targets by a second pathway that does not require VHL-1 (labeled pathway 2 
here).   B) Initial alternative models for the VHL-1-independent functions of EGL-9 (pathway 2).  
Each model predicts a different combination of experimental outcomes.  Model (a) postulates that 
pathway 2 (like pathway 1) requires hydroxylation of HIF-1 proline 621.  Model (b) is that EGL-9 
hydroxylates a different target to inhibit HIF-1 transcriptional activity.  This model predicts that all 
EGL-9 functions would be abrogated by mutations or treatments that eliminated EGL-9 hydroxylase 
activity.  Model (c) is that EGL-9 represses HIF-1-mediated transcription by a mechanism that does 
not require EGL-9 hydroxylase activity.   
 
Figure 2.  The HIF-1(P621G) mutation does not prevent egl-9-mediated repression of HIF-1 activity:  
A) In control experiments, the transgene encoding wild-type hif-1, rescued expression of 
Pnhr-57::GFP in hif-1(ia04) mutant animals, as measured by protein blots.  The egl-9(sa307) 
loss-of-function mutation dramatically increased expression of the Pnhr-57::GFP reporter. “+” 
designates the wild-type allele.   B,C) To determine whether the HIF-1(P621G) mutation abrogated 
all regulation by egl-9, the expression of two HIF-1 targets, Pnhr-57::GFP and K10H10.2, were 
compared in egl-9(+) and egl-9(sa307) animals.  These experiments were conducted in hif-1(ia04) 
mutants rescued by the hif-1(P621G)::tag transgene.  B) The HIF-1(P621G) mutation did not 
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prevent repression of Pnhr-57::GFP by egl-9. Pnhr-57::GFP expression was assayed by protein blots .  
This result was consistent across three independently isolated hif-1(P621G)::tag transgenic lines 
(iaIs32, iaIs33 and iaIs34) (p<0.01 in each case).  C)  The hif-1(P621G) iaIs32 mutation does not 
abolish regulation of K10H10.2 expression by egl-9.  Quantitative RT-PCR experiments established 
a significant difference in K10H10.2 mRNA levels between egl-9(+) and egl-9(sa307) (p<0.05). 
 
Figure 3.  Differential effects of hypoxia or iron chelators on the two EGL9 pathways:  A) In 
control experiments, hypoxia (0.5% oxygen, 1 hour) or the iron chelator 2, 2 -dipyridyl (DIP, 200μM, 
4 hours) increased HIF-1 protein to levels similar to those caused by loss-of-function mutations in 
vhl-1 or egl-9.  The bar graph shows HIF-1 protein levels relative to that in untreated vhl-1(+) and 
egl-9(+) animals.  In these strains, the only functional copy of hif-1 is the epitope-tagged transgene. 
The error bars indicate the standard errors from three independent biological replicates.  B)  To 
determine whether hydroxylase inhibitors had similar effects on HIF-1 target genes as a mutation in 
egl-9, expression of the reporter was assayed by protein blots.  Hypoxia or DIP treatment increased 
expression of the reporter to levels found in vhl-1 loss-of-function mutants, but the treatments did not 
completely phenocopy the effects of a loss-of-function mutation in egl-9.  In the bar graph, 
Pnhr-57::GFP levels are shown relative to that in untreated vhl-1(+) and egl-9(+) animals. The 
vhl-1(ok161) and egl-9(sa307) mutations are strong loss-of-function alleles.  “+” designates the 
wild-type allele.  The bars represent average values from 3 independent replicates, and the error bars 
reflect standard error.  The statistics were comparing the hypoxia or DIP treated data to untreated 
data with the same genotype.  Asterisks represent statistically significant differences between 
treatment and room air for animals of the same genotype; *: p< 0.05 ; **: p<0.01.   
   
Figure 4.  The egl-9(H487A) mutation does not abolish egl-9-mediated repression of HIF-1 activity: 
A) Alignment of human PHD2 and C. elegans EGL-9 at the region around EGL-9 His487.  B) 
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Diagrams of egl-9 minigenes.  The minigenes are fusions of genomic and cDNA sequences.  Boxes 
represent coding regions.  GFP is fused in-frame to egl-9.  The H487A mutation disrupts the Fe(II) 
binding pocket in EGL-9 and impairs EGL-9 catalytic activity.  C) In egl-9(sa307) mutants, HIF-1 
destabilization was rescued by the transgene coding for wildtype egl-9 (iaIs38), but not by the 
egl-9(H487A) transgenes (iaEx101, iaEx104, or iaEx110).  AHA-1 protein levels have been shown 
to be unaffected by severe loss-of-function mutations in egl-9 or vhl-1 (SHEN et al. 2006), and AHA-1 
serves as a loading control.  D, E) Transgenes expressing either wild-type egl-9 or egl-9(H487A) can 
suppress expression of HIF-1 targets in an egl-9(sa307) background.  D) In strains carrying the 
wild-type egl-9 transgene, repression of Pnhr-57::GFP is more effective and is inhibited by DIP.  In 
strains expressing egl-9(H487A), DIP does not have a significant effect. The bar graph shows 
averages of Pnhr-57::GFP protein levels from 3 biological replicates, normalized to expression levels 
in an egl-9(sa307) mutant. The asterisk indicates DIP causes a statistically significant difference in 
the expression of the reporter (*: p<0.05) and n.s. is no significant difference.  E) The wild-type 
egl-9 transgene and the egl-9(H487) mutant transgene were able to repress K10H10.2 mRNA levels 
in an egl-9(sa307) mutant.  K10H10.2 mRNA levels were also assayed in wild-type N2 and in 
vhl-1-deficient animals for comparison. The bar graph shows the relative K10H10.2 mRNA levels in 
each strain, compared to egl-9(sa307) and the error bars reflect standard error.  n.s.:  no significant 
difference; *: p< 0.05 ; **: p<0.01 
 
Figure 5.  Characterization of egl-9 loss-of-function alleles: A) Diagram of egl-9 exons and introns 
and description of new mutations.  Boxes represent exons for the predominant egl-9 mRNA isoform, 
and the exons encoding the MYND or hydroxylase domains are filled.  Lines represent deleted 
sequences in the gk277, sa307, or ok478 alleles; arrows indicate the positions of the ia58 and ia61 
mutations; and the position of the ia60 transposon insertion is shown. The alleles isolated in this 
study are described in the table. B) Relative effects of egl-9 mutations on HIF-1 protein levels.  
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These animals carry the hif-1(ia04) deletion mutation, and hif-1 function is restored by the hif-1::tag 
transgene.  The numbers above the lanes reflect HIF-1 levels relative to those detected in 
egl-9(sa307) mutants, as determined from 3 replicate experiments.  C) Expression of the 
Pnhr-57::GFP reporter in egl-9 mutants, relative to animals homozygous for the egl-9(sa307), a 
strong loss-of-function egl-9 allele. The bars represent average values relative to those in 
egl-9(sa307), a severe egl-9 mutant allele, from 3 independent replicates, and the error bars reflect 
standard error. 
 
Figure 6.  The egl-9(gk277) mutation removes the MYND zinc finger domain, but has little effect on 
HIF-1 protein levels or on expression of HIF-1 targets:  A)  The egl-9(gk277) mutation does not 
significantly increase expression of HIF-1 protein in vhl-1(+) or vhl-1(ok161).  B, C) The 
egl-9(gk277) mutation has a significant effect on the expression of HIF-1 target genes, but these 
effects are much smaller than the severe egl-9(sa307) mutation. The bar graphs show the expression 
of the Pnhr-57::GFP reporter (B) and the endogenous HIF-1 target gene K10H10.2 (C) in each strain, 
relative to the values for animals carrying wild-type alleles of vhl-1 and egl-9. The bars represent 
average values from 3 independent replicates, and the error bars reflect standard error.  n.s.:  no 
significant difference; *: p< 0.05. 
 
 
 
 
 
 
 
     59
FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
     60
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     61
 
     62
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     63
 
 
 
 
 
 
 
 
 
 
     64
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     65
SUPPLEMENTAL MATERIALS 
Methods 
 
Building egl-9 plasmids: To create Pegl-9::egl-9::tag plasmid, 1.6 kb of sequence 5’ to the egl-9 
translational start was amplified and cloned into the pPD95.75 vector (from Andrew Fire) (primers: 
CGCGCATGCGTGTATGTGTGTGAAAGAG and GCGGTCGACGCAACTT 
TTTTCTGTCACATTCAG).  The remaining coding sequence for egl-9 (exons 3 to end) was 
amplified from cDNA, using primers 5’GCGGTCGACCACATGACATGAGCA 
GTGCCCCAAATG and 5’ GCGGGATCCG AGATGTAATACTCTGGGTTTGTGGAAGG.  The 
resulting fragment was digested with SalI and BamHI and ligated to the construct.  Finally, the 
genomic sequence including the first three egl-9 exons was amplified (primers: 
5’GCGGTCGACCACATGACATGAGCAGTGCCCCAAATG and 
5‘GGATTGGAATCGATGGCTCTGG) and added to the construct using SalI and ClaI restriction 
sites.  Pegl-9::egl-9 (H487A)::tag is made by altering codon His487 to Ala. 
 
Western analysis: For HIF-1 blot, 40-100 synchronized L4 stage animals were used. For 
Pnhr-57::GFP analysis, the numbers of L4 animals are: 2-4 for egl-9 mutants except for gk277 allele, 
20-40 for vhl-1 mutant, and 100 for vhl-1(+) and egl-9(+) strain. The worm samples were boiled in 
10ul M9 and 10ul 2x SDS buffer [50mM Tris-HCl PH6.8, 10%(v/v) glycerol, 2% (w/v) SDS, 100mM 
DTT, 0.1% (w/v) bromphenol blue] for 10 minutes before loading to 10% or 12% polyacrylamide 
gels. After separation, proteins were transferred to nitrocellulose membranes.  The blots were probed 
with monoclonal antibodies recognizing the following epitopes: GFP (antibody from Roche at 1:1000 
dilution); HA (antibody from Cell Signaling Technology clone 6E2 at 1:1000 dilution); myc (mouse 
ascites, clone 9E10, from the Developmental Studies Hybridoma Bank at 1:1000 dilution), or AHA-1 
(JIANG et al. 2001) (1:100 dilution). The secondary antibody (goat anti-mouse IgG+IgM from Biorad) 
was diluted 1:2000. The relative intensity of protein bands were quantified by Image J software. 
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Figures 
  
 
FIGURE S1. The HIF-1 (P621G) mutation stabilizes HIF-1 protein.  A)  Diagrams of 
minigenes that direct expression of epitope-tagged HIF-1 or HIF-1 (P621G). These 
transgenes are described as Phif-1::hif-1::tag and Phif-1::hif-1 (P621G)::tag.  Boxes 
represent translated regions. The asterisk indicates sequence encoding proline 621, which 
was mutated to code for glycine in the P621G construct.  B,C) Representative protein blots 
to analyze the expression of epitope-tagged HIF-1 or HIF-1 (P621G) in transgenic animals. 
Each strain shown carried the hif-1 (ia04) deletion allele, and HIF-1 function was restored by 
an integrated copy of one of the hif-1 transgenes.  Blots were probed with antibodies that 
recognize the myc epitope.  B) Regulation of epitope-tagged HIF-1 by egl-9 and vhl-1 in 
transgenic C. elegans.  egl-9 (sa307) and vhl-1 (ok161) are strong loss-of-function alleles, 
and “+” represents the allele present in wild-type C. elegans (Bristol N2).  AHA-1 protein 
levels are unchanged in these mutant backgrounds.  C) The P621G mutation prevented 
vhl-1- and egl-9-mediated destabilization of HIF-1 protein.  Data from at least three 
independent biological replicates were analyzed to determine whether loss-of-function 
mutations in vhl-1 or egl-9 resulted in statistically significant differences in HIF-1 or HIF-1 
(P621G) protein levels.  n.s.:  no significant difference; *: p< 0.05; **: p<0.01 
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Figure S2.  Relative expression levels of epitope-tagged EGL-9 protein in transgenic lines.  
Protein blots were probed with primary antibodies recognizing the GFP tag on the 
egl-9::GFP and egl-9 (H487A)::GFP transgenes and AHA-1, which was assayed as a loading 
control. While the expression of EGL-9 protein in iaEx104  is about 3 folds lower than in 
iaIs38, iaEx101, and iaEx110 transgenes, iaEx104 suppresses hif-1 targets as well (Figure 4).  
This suggests that there may be a threshold level of EGL-9 required for rescue, and that this 
threshold is achieved by all 4 strains. These data are shown as a representative blot (A.) and a 
bar chart summarizing three biological replicates (B). 
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Figure S3.  Sequencing of existing cDNAs reveals multiple egl-9 mRNA isoforms.  Boxes 
represent exons and lines represent introns. MYND and prolyl hydroxylase domains are 
filled with black. Nineteen cDNAs from the National Institute of Genetics, Mishima, Japan 
were sequenced in full, and the number cDNAs of each egl-9 isoform in that collection is 
shown in the righthand column.  The cDNA sequences have been submitted to 
www.wormbase.org. 
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Figure S4. Diagram describing the MOS1-mediated screen to identify alleles that caused 
over-expression of Pnhr-57::GFP.  The extrachromosomal array that included the MOS1 
transposon also carried the Pmyo-2::GFP pharyngeal marker.  The array containing Phsp:: 
transposase included the Punc-122::GFP gene, which labels coelomocytes.  Both starting 
strains carried the Pnhr-57::GFP reporter. F1 eggs that were laid between 18-40 hours after 
heatshock treatment were collected.  Animals over-expressing the HIF-1 reporter were 
isolated.  Inverse PCR and complementation tests with existing egl-9 alleles were used to 
map the mutation site. 
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Tables 
 
Table S1:  Descriptions of mutant alleles used in this study  
Gene name Allele name Description References 
hif-1 ia04 deletion, loss of function (JIANG et al. 2001) 
vhl-1 ok161 deletion, loss of function (EPSTEIN et al. 2001) 
sa307 deletion, loss of function (DARBY et al. 1999) 
ok478 deletion, loss of function * 
gk277 deletion, weak loss of function * 
sa330 loss of function (DARBY et al. 1999) 
ia58 loss of function This study 
ia60 loss of function This study 
egl-9 
ia61 loss of function This study 
unc-119 ed3 loss of function (MADURO and 
PILGRIM 1995) 
*  These alleles were generated by the C. elegans knock-out consortium.   
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Table S2:  Transgenes used in this study 
Construct assayed * Integration 
event or array 
Description and co-transformation marker ** 
Pnhr-57::GFP iaIs07 Integrated (SHEN et al. 2006) 
Phif-1:hif-1::tag iaIs28 Integrated with unc-119 (+) 
iaIs32 Integrated with unc-119 (+) 
iaIs33 Integrated with unc-119 (+) 
Phif-1:hif-1 
(P621G)::tag 
iaIs34 Integrated with unc-119 (+) 
Pegl-9::egl-9::tag iaIs38 Integrated with unc-119 (+) 
iaEx101 Extrachromosomal array with unc-119 
iaEx104 Extrachromosomal array with unc-119 
Pegl-9::egl-9 
(H487)::tag 
iaEx110 Extrachromosomal array with unc-119 
*  The promoter is listed first, followed by the coding sequences. 
** Integration events were achieved by microparticle bombardment (PRAITIS et al. 2001) and were 
backcrossed at least four times prior to further characterization.   
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Table S3:  Strains described in this study 
Strains used to compare the regulation and function of HIF-1 and HIF-1 (P621G) 
Strain  Genotype 
ZG430 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (sa307)  hif-1 (ia04) V; 
iaIs28[Phif-1::hif-1a::tag  unc-119 (+)] 
ZG432 iaIs07[Pnhr-57::gfp unc-119 (+)] IV;  hif-1 (ia04) V; vhl-1 (ok161) X; 
iaIs28[Phif-1::hif-1a::tag  unc-119 (+)] 
ZG433 iaIs07[Pnhr-57::gfp unc-119 (+)] IV;  hif-1 (ia04) V; iaIs28 [Phif-1::hif-1a::tag  
unc-119 (+)] 
ZG551 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (sa307)  hif-1 (ia04) V; 
iaIs32[Phif-1::hif-1a(P621G)::tag  unc-119 (+)] 
ZG552 iaIs07[Pnhr-57::gfp unc-119 (+)] IV;  hif-1 (ia04) V; 
iaIs32[Phif-1::hif-1a(P621G)::tag  unc-119 (+)] 
ZG553 iaIs07[Pnhr-57::gfp unc-119 (+)] IV;  hif-1 (ia04) V; vhl-1 (ok161) X;  iaIs32 
[Phif-1::hif-1a(P621G)::tag  unc-119 (+)] 
ZG555 iaIs07[Pnhr-57::gfp unc-119 (+)] IV;  egl-9 (sa307) hif-1 (ia04) V; iaIs33 
[Phif-1::hif-1a(P621G)::tag  unc-119 (+)] 
ZG557 iaIs07[Pnhr-57::gfp unc-119 (+)] IV;  egl-9 (sa307) hif-1 (ia04) V; iaIs34 
[Phif-1::hif-1a(P621G)::tag  unc-119 (+)] 
ZG677 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; hif-1 (ia04) V; iaIs33 
[Phif-1::hif-1a(P621G)::tag  unc-119 (+)] 
ZG678 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; hif-1 (ia04) V; vhl-1 (ok161) X; iaIs33 
[Phif-1::hif-1a(P621G)::tag  unc-119 (+)] 
ZG679 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; hif-1 (ia04) V; iaIs34 
[Phif-1::hif-1a(P621G)::tag  unc-119 (+)] 
ZG680 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; hif-1 (ia04) V; vhl-1 (ok161) X; iaIs34 
[Phif-1::hif-1a(P621G)::tag  unc-119 (+)] 
Strains used to analyze the effects of hypoxia and DIP 
Strain Genotype 
ZG119 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; vhl-1 (ok161) 
ZG120 iaIs07[Pnhr-57::gfp unc-119 (+)] IV 
ZG302 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (sa307) V 
ZG430 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (sa307)  hif-1 (ia04) V; 
iaIs28[Phif-1::hif-1a::tag  unc-119 (+)] 
ZG432 iaIs07[Pnhr-57::gfp unc-119 (+)] IV;  hif-1 (ia04) V; vhl-1 (ok161) X; 
iaIs28[Phif-1::hif-1a::tag  unc-119 (+)] 
ZG433 iaIs07[Pnhr-57::gfp unc-119 (+)] IV;  hif-1 (ia04) V; iaIs28 [Phif-1::hif-1a::tag  
unc-119 (+)] 
Strains generated for MOS1 mutagenesis screen 
ZG399 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; oxEx166[hspp::Mostransposase lin-15 (+) 
Punc-122::GFP] 
ZG405 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; oxEx229[Mos1 myo-2::GFP] 
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Continuation of Table S3 
Strains to compare the regulation and functions of EGL-9 and EGL-9 (H487A) 
ZG494 unc-119 (ed3) III; egl-9 (sa307) V;  iaIs38[Pegl-9::egl-9::tag  unc-119 (+)] 
ZG676 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (sa307) hif-1 (ia04) V;  
iaIs38[Pegl-9::egl-9::tag  unc-119 (+)] 
ZG681 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (sa307) V; vhl-1 (ok161) X;  
iaIs38[Pegl-9::egl-9::tag  unc-119 (+)] 
ZG682 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (sa307) hif-1 (ia04) V; 
iaIs38[Pegl-9::egl-9::tag  unc-119 (+)], iaIs28 [Phif-1::hif-1a::tag  unc-119 (+)]
ZG686 unc-119 (ed3) III; egl-9 (sa307) V;  iaEx101[Pegl-9::egl-9 (H487A)::tag  
unc-119 (+)] 
ZG691 unc-119 (ed3) III; egl-9 (sa307) V;  iaEx104[Pegl-9::egl-9 (H487A)::tag  
unc-119 (+)] 
ZG696 iaIs07[Pnhr-57::gfp unc-119 (+)] IV;  egl-9 (sa307) V; iaIs38[Pegl-9::egl-9::tag  
unc-119 (+)] 
ZG700 iaIs07[Pnhr-57::gfp unc-119 (+)] IV;egl-9 (sa307) hif-1 (ia04) V;  
iaEx104[Pegl-9::egl-9 (H487A)::tag  unc-119 (+)] 
ZG701 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (sa307) hif-1 (ia04) V;  iaIs28 
[Phif-1::hif-1a::tag  unc-119 (+)]  iaEx110[Pegl-9::egl-9 (H487A)::tag  
unc-119 (+)] 
ZG702 unc-119 (ed3) III; egl-9 (sa307) V;  iaEx110[Pegl-9::egl-9 (H487A)::tag  
unc-119 (+)] 
ZG704 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (sa307) V;  iaEx110[Pegl-9::egl-9 
(H487A)::tag  unc-119 (+)] 
ZG707 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (sa307) V;  iaEx104 [Pegl-9::egl-9 
(H487A)::tag  unc-119 (+)] 
ZG708 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (sa307) hif-1 (ia04) V;  iaIs28 
[Phif-1::hif-1a::tag  unc-119 (+)] iaEx101[Pegl-9::egl-9 (H487A)::tag  unc-119 
(+)] 
Additional strains generated to characterize new and existing egl-9 loss-of-function alleles 
ZG444 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (ia58) V 
ZG447 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (gk277) V; vhl-1 (ok161) X 
ZG448 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (ia60) V 
ZG449 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (ia61) V 
ZG457 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (gk277)  hif-1 (ia04) V; iaIs28 
[Phif-1::hif-1a::tag  unc-119 (+)] 
ZG458 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (gk277)  hif-1 (ia04) V; vhl-1 (ok161) 
X; iaIs28 [Phif-1::hif-1a::tag  unc-119 (+)] 
ZG492 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (ok478) V 
ZG493 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (sa330) V 
ZG671 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (ia58) hif-1 (ia04) V;  iaIs28 
[Phif-1::hif-1a::tag  unc-119 (+)] 
ZG672 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (ia60) hif-1 (ia04) V;  iaIs28 
[Phif-1::hif-1a::tag  unc-119 (+)] 
ZG673 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (ia61) hif-1 (ia04) V;  iaIs28 
[Phif-1::hif-1a::tag  unc-119 (+)] 
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Continuation of Table S3 
ZG674 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (ok478) hif-1 (ia04) V;  iaIs28 
[Phif-1::hif-1a::tag  unc-119 (+)] 
ZG675 iaIs07[Pnhr-57::gfp unc-119 (+)] IV; egl-9 (sa330) hif-1 (ia04) V;  iaIs28 
[Phif-1::hif-1a::tag  unc-119 (+)] 
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CHAPTER 3. C. ELEGANS SWAN-1 BINDS TO EGL-9 AND 
MODULATES HYPOXIA RESPONSE AND RESISTANCE TO THE 
BACTERIAL PATHOGEN PSEUDOMONAS AERUGINOSA PAO1 
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ABSTRACT 
Pseudomonas aeruginosa is a nearly ubiquitous human pathogen, and infections can be lethal to 
patients with impaired respiratory and immune systems.  Prior studies have established that strong 
loss-of-function mutations in the egl-9 gene protect the nematode C. elegans from P. aeruginosa 
PAO1 fast killing.  EGL-9 inhibits the HIF-1 transcription factor via two pathways. First, EGL-9 is 
the enzyme that targets HIF-1 for oxygen-dependent degradation via the VHL-1 E3 ligase. Second, 
EGL-9 inhibits HIF-1-mediated gene expression through a VHL-1-independent mechanism.  Here, 
we show that a loss-of-function mutation in hif-1 suppresses P. aeruginosa PAO1 resistance in egl-9 
mutants.  Importantly, we find stabilization of HIF-1 protein is not sufficient to protect C. elegans 
from P. aeruginosa PAO1 fast killing.  Mutations that inhibit both EGL-9 pathways result in higher 
levels of HIF-1 activity and confer resistance to the pathogen.  Using forward genetic screens, we 
identify additional mutations that confer resistance to P. aeruginosa.  In genetic backgrounds that 
stabilize C. elegans HIF-1 protein, loss-of-function mutations in swan-1 increase the expression of 
hypoxia response genes and protect C. elegans from P. aeruginosa fast killing.  SWAN-1 is an 
evolutionarily conserved WD-repeat protein belonging to the AN11 family.  Using yeast two-hybrid 
and co-immunoprecipitation assays, we show that EGL-9 forms a complex with SWAN-1.  These 
                                                
3 1 Primary researcher and author 
4 Author for correspondence 
     76
data support a model in which SWAN-1 and EGL-9 act in a common pathway to regulate HIF-1 
transcriptional activity and modulate resistance to P. aeruginosa PAO1 fast killing. 
 
INTRODUCTION 
Pseudomonas aeruginosa is a ubiquitous bacterial pathogen that can infect a wide range of 
animals and plants, and hospital-acquired P. aeruginosa infections are often lethal to patients with 
respiratory ailments or immune system dysfunction (GOMEZ and PRINCE 2007; LEE et al. 2005). The 
cyanide produced by P. aeruginosa is thought to contribute to the potentially devastating effects of P. 
aeruginosa respiratory infections in cystic fibrosis patients(ANDERSON et al. 2010).  
Antibiotic-resistant strains of P. aeruginosa are becoming more prevalent, and it is increasingly 
important to understand the pathogenicity of this microbe and the mechanisms that enable resistance 
(PAGE and HEIM 2009a; PAGE and HEIM 2009b).  
During infection and inflammation, multicellular tissues must adapt to changing levels of oxygen.  
The hypoxia-inducible factor (HIF) transcription complex mediates most of the transcriptional 
responses to hypoxia (low oxygen) (SEMENZA 2001; SHEN et al. 2005).  While HIF transcription 
complexes have been shown to play key roles in mammalian innate immunity, the mechanisms by 
which HIF regulatory networks influence pathogenicity and disease progression are not yet fully 
understood (HONG et al. 2009; NIZET and JOHNSON 2009; RIUS et al. 2008; WALMSLEY et al. 2008; 
ZINKERNAGEL et al. 2007).   
In recent years, the nematode Caenorhabditis elegans has emerged as a powerful genetic system 
to study innate immunity and resistance to bacterial pathogens (ABALLAY and AUSUBEL 2002; 
ALEGADO et al. 2003; EWBANK 2003; KURZ and EWBANK 2000; MYLONAKIS et al. 2003; TAN 2002). 
Many of the genes that contribute to C. elegans pathogen resistance are evolutionarily conserved 
(KIM and AUSUBEL 2005; NICHOLAS and HODGKIN 2004; SCHULENBURG et al. 2004).  Interestingly, 
there is a strong correlation between C. elegans genes that mediate resistance to bacterial pathogens 
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and genes that protect C. elegans from stresses and extend lifespan (EVANS et al. 2008; KURZ and 
TAN 2004; LAWS et al. 2004; SINGH and ABALLAY 2006; TROEMEL et al. 2006).  
Loss-of-function mutations in the C. elegans egl-9 gene enable the animals to survive fast killing 
by P. aeruginosa PAO1 (DARBY et al. 1999; GALLAGHER and MANOIL 2001).  While some 
Pseudomonas strains (such as PA14 on NGM growth media) kill C. elegans slowly through 
colonization in the gut, logarithmically growing P. aeruginosa PAO1 emits cyanide and kills C. 
elegans within hours (ABALLAY and AUSUBEL 2002; DARBY et al. 1999; GALLAGHER and MANOIL 
2001; TAN et al. 1999).  C. elegans egl-9 mutants are also resistant to Crystal or Vibrio cholerae 
pore-forming toxins (BELLIER et al. 2009).  The egl-9 gene encodes a 2-oxoglutarate-dependent 
dioxygenase that hydroxylates the HIF-1 transcription factor.  Once HIF-1 is hydroxylated, it 
interacts with the VHL-1 E3 ligase and is targeted for proteasomal degradation (EPSTEIN et al. 2001).  
EGL-9 has also been shown to inhibit HIF-1 transcriptional activity via a vhl-1-independent pathway 
that has little or no requirement for EGL-9 hydroxylase activity (SHAO et al. 2009; SHEN et al. 2006). 
Moderate over-expression of HIF-1 has been shown to increase resistance to heat and to increase 
adult longevity in C. elegans (CHEN et al. 2009; MEHTA et al. 2009; TREININ et al. 2003; ZHANG et al. 
2009).  
In this study, we directly test the hypothesis that increased expression and activation of the HIF-1 
transcription factor in egl-9 mutants protects C. elegans from P. aeruginosa PAO1 fast killing.  We 
show that resistance to P. aeruginosa fast killing requires both stabilization of HIF-1 protein and 
derepression of HIF-1-mediated gene expression.  Using forward genetic screens, we identify 
additional mutations that confer resistance to P. aeruginosa PAO1 fast killing.  This leads to the 
discovery that SWAN-1 inhibits HIF-1 transcriptional activity and modulates resistance to P. 
earuginosa PAO1 fast killing. SWAN-1 is an evolutionarily conserved protein with WD40 repeats 
(YANG et al. 2006). Further, we demonstrate that SWAN-1 interacts with EGL-9 protein in yeast 
two-hybrid and co-immunoprecipitation studies. 
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RESULTS 
 
hif-1 is required for the egl-9-mediated resistance to PAO1 fast killing: The egl-9 (sa307) strong 
loss-of-function mutation has been shown to protect C. elegans from P. aeruginosa PAO1 fast killing 
(DARBY et al. 1999; GALLAGHER and MANOIL 2001) (Figure 1A).  We tested the hypothesis that 
egl-9-mediated resistance to fast killing required hif-1 function.  As shown in Figure 1A, the 
hif-1(ia04) loss-of-function allele totally suppressed the egl-9-mediated resistance phenotype.  The 
rate at which the egl-9, hif-1 double mutant was killed by the pathogen was very similar to the killing 
curves for wild-type or hif-1 (ia04) animals (Figure1A, Table S1).  A prior study had shown that the 
fast killing of C. elegans by P. aeruginosa required cyanide synthesis  (GALLAGHER and MANOIL 
2001).  Consistent with this, we found that while P. aeruginosa PAO1 killed wild-type or 
hif-1-deficient C. elegans within 2 hours, the hydrogen cyanide synthase mutant P. aeruginosa 
MP507 did not kill C. elegans in this time interval (Table S2). 
We next investigated which EGL-9 functions were most critical to the P. aeruginosa PAO1 fast 
killing phenotype.  EGL-9 regulates HIF-1 via at least two pathways: EGL-9 is the oxygen-sensitive 
enzyme that targets HIF-1 protein for degradation through the VHL-1 pathway, and EGL-9 inhibits 
HIF-1-mediated transcriptional activity by a vhl-1-independent mechanism (BISHOP et al. 2004; 
SHAO et al. 2009; SHEN et al. 2006).  We first tested the hypothesis that stabilization of HIF-1 
protein was sufficient to increase resistance to P. aeruginosa PAO1 fast killing.  The HIF-1 (P621G) 
mutation precludes hydroxylation of HIF-1 by EGL-9 and stabilizes HIF-1 protein (EPSTEIN et al. 
2001; SHAO et al. 2009; ZHANG et al. 2009).  We assayed four transgenic strains, each expressing 
either wild-type HIF-1 or the HIF-1 (P621G) stabilized protein.  Remarkably, none of transgenic 
strains were resistant to P. aeruginosa PAO1, as they died at rates similar to wild-type animals 
(Figure 1B, Table S3).  Consistent with this result, the vhl-1(ok161) mutation did not protect C. 
elegans from fast killing (Table S4). 
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Genetic screens identify mutations in swan-1 and rhy-1 that increase HIF-1-mediated transcription 
and protect C. elegans from P. aeruginosa PAO1 fast killing: The results thus far suggested that 
resistance to fast killing required multiple EGL-9 functions.  To gain insight to the mechanisms by 
which EGL-9 repressed HIF-1 transcriptional activity and to better understand P. aeruginosa PAO1 
pathogenicity, we conducted forward genetic screens. Using chemical or transposon-mediated 
mutagenesis, we screened for mutations in C. elegans that caused dramatic over-expression of HIF-1 
target genes.  As a primary screen, we assayed for the increased expression of Pnhr-57::GFP, a 
reporter that is expressed at very low levels in wild-type animals and is expressed at high levels in 
egl-9 mutants (SHAO et al. 2009; SHEN et al. 2006).  These screens identified novel loss-of-function 
mutations in rhy-1 (Table S5).  Prior studies had shown that rhy-1 encoded a multipass 
transmembrane protein, and loss-of-function mutations in rhy-1 had been shown to elevate hif-1 
mRNA levels slightly and to increase HIF-1 transcriptional activity (SHEN et al. 2006).  As shown in 
Table 1, the new rhy-1 loss-of-function alleles were resistant to P. aeruginosa PAO1 fast killing, and 
rhy-1-mediated resistance was completely suppressed by the hif-1 (ia04) strong loss-of-function 
mutation.  
Reasoning that the effects of some mutations that derepressed HIF-1 activity might only be 
evident if HIF-1 protein were stable, we crossed a vhl-1 loss-of-function mutation into the parental 
strain.  One such screen identified ia50, a mutation that enhanced expression of Pnhr-57::GFP 
reporter in vhl-1(ok161) mutants (compare Figure 2C to 2B).  While vhl-1(ok161) animals 
overexpressed the reporter in the intestine, the ia50 mutation expanded expression of Pnhr-57::GFP 
to other tissues, including the hypodermis and the excretory cells (Figure 2C).  The enhanced GFP 
expression phenotype of ia50 was completely recessive. The ia50, vhl-1(ok161) double mutants had 
morphological defects that were similar to those seen in egl-9 loss-of-function mutants, including egg 
laying defects and reduced fertility (Figure 2G and data not shown). 
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Genetic mapping with single-nucleotide polymorphisms placed ia50 near +5.67 map units on 
chromosome five of the C. elegans genome (Figure 3A).  Cosmid rescue experiments further 
delimited a genomic region that could restore a wild-type Pnhr-57::GFP expression pattern from ia50 
mutant animals (Figure 3A). We sequenced the genes in this region and found that ia50 mutants 
carried a single nucleotide mutation in the splice acceptor site for swan-1 (F53C11.8) exon 3 (Figure 
3A, 3B).  Full length cDNA sequencing confirmed that ia50 mutants did not splice intron 2 from the 
swan-1 mRNA, and this introduced an early stop codon.  SWAN-1 belongs to the AN11 family of 
WD repeat proteins, which includes Petunia AN11, Arabidopsis TTG1, zebrafish Wdr68, and human 
HAN11 (DE VETTEN et al. 1997; DRESSEL and HEMLEBEN 2009; NISSEN et al. 2006; SKURAT and 
DIETRICH 2004) . WD repeat proteins have beta propeller tertiary structures and often serve as 
platforms for the assembly of larger protein complexes. 
To further test the hypothesis that the ia50 mutant phenotype was due to defects in the swan-1 
gene, we used bacterially mediated RNAi to deplete swan-1 mRNA. swan-1 RNAi increased the 
expression of Pnhr-57::GFP, as assayed by protein blots.  In control experiments, RNAi for a 
neighboring gene, swan-2, did not change the expression of the reporter (compare to the empty vector 
control in Figure 3C).  
Prior studies had characterized the swan-1(ok267) deletion mutation as a strong loss-of-function 
allele (YANG et al. 2006) (illustrated in Figure 3A).  When HIF-1 protein was stabilized by the vhl-1 
(ok161) mutation, the swan-1(ok267) allele increased expression of the Pnhr-57::GFP reporter 
(Figure 3D).  This phenotype was suppressed by a loss-of-function mutation in hif-1.  
Having established that swan-1 negatively regulated Pnhr-57::GFP expression, we next asked 
whether a strong loss-of-function mutation in swan-1 also increased the expression of other HIF-1 
target genes.  Prior studies had demonstrated that K10H10.2 and F22B5.4 were induced by hypoxia 
in a hif-1-dependent manner and that they were over-expressed in vhl-1, egl-9, or rhy-1 
loss-of-function mutants (BISHOP et al. 2004; EPSTEIN et al. 2001; SHAO et al. 2009; SHEN et al. 
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2006). As shown in Figure 4A and 4B, mRNA levels for both K10H10.2 and F22B5.4 increased in 
swan-1(ok267), vhl-1(ok161) double mutants, relative to the vhl-1(ok161) single mutant.  These data 
represent at least three biological replicates of realtime RT-PCR experiments. As shown in Figure 4C, 
the swan-1 deletion mutation did not have a significant effect on HIF-1 protein levels.   
 
In the presence of stabilized HIF-1, a swan-1 loss-of-function mutation protected C. elegans from P. 
aeruginosa fast killing: We hypothesized that the combination of HIF-1 stabilization and deletion of 
swan-1 might result in a P. aeruginosa resistance phenotype similar to that of egl-9 or rhy-1 mutants.  
Stabilization of HIF-1, through either the stabilizing P621G mutation in HIF-1 or by mutation of the 
vhl-1 E3 ligase, was not sufficient to protect C. elegans from P. aeruginosa PAO1 fast killing (Figure 
1B and 5A).  However, swan-1(ok267), vhl-1(ok161) double mutants were much more resistant than 
wild-type animals (>40% survived after two hours) (Figure 5A and Table S4).  As expected, this 
resistance was suppressed by a hif-1 loss-of-function mutation (Table S6).  Similarly, in transgenic 
animals expressing HIF-1(P621G), the swan-1(ok267) mutation enabled almost 100% survival after 
two hours on a P. aeruginosa PAO1 lawn (Figure 5B).  Similar results were obtained using an 
independent hif-1(P621G) transgenic line (Table S7).   
 
Interaction between the EGL-9 and SWAN-1 proteins: The genetic data left open the possibility that 
SWAN-1 and EGL-9 acted in concert to inhibit HIF-1 activity, but do the two proteins physically 
interact? To address this, we performed yeast-two-hybrid assays.  In these assays, the EGL-9 
catalytic domain was fused to the Gal-4 DNA binding domain.  In control experiments, this protein 
fusion by itself did not activate expression of reporter genes that were positively regulated by Gal-4 
upstream activating sequences.  When the EGL-9 protein fusion was combined with a fusion of 
SWAN-1 and the Gal-4 activation domain, the two proteins interacted to allow yeast growth on 
nutrient deficient plates (-Ade/-His/-Leu/-Trp) and to activate β-galactosidase expression (Figure 6A).   
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To further define the regions of SWAN-1 that interacted with EGL-9, we assayed five SWAN-1 
deletions, and these results are summarized in Figure 6B.  A construct containing only the first three 
WD repeats of SWAN-1 was able to interact strongly in yeast two-hybrid assays, whereas a construct 
that lacked the first four WD repeats did not interact with EGL-9.  
To further test the hypothesis that EGL-9 and SWAN-1 could interact in a common complex, we 
conducted co-immunoprecipitation studies. In these experiments, the EGL-9 catalytic domain was 
fused to maltose binding protein and expressed in E. coli.  A SWAN-1::GFP fusion protein was 
expressed in C. elegans and purified with a GFP-specific monoclonal antibody.  In control 
experiments, GFP alone was purified from worms.  The SWAN-1::GFP and MBP::EGL-9 proteins 
were co-incubated, and unbound proteins were washed away.  As shown in Figure 6C, MBP::EGL-9 
was coimmunoprecipitated with SWAN-1::GFP. 
Prior studies had demonstrated that SWAN-1 interacted with Rac GTPases and the Rac effector 
UNC-115, and swan-1 had been shown to repress Rac GTPase activity in neurons (YANG et al. 2006).  
Thus, we considered models in which swan-1 repressed HIF-1 activity by inhibiting Rac GTPases.  
However, depletion of unc-115, rac-2, ced-10 or mig-2 by mutation or RNAi did not abolish the 
induction of Pnhr-57::GFP expression in swan-1 (ok267), vhl-1 (ok161) animals (Figure S1).  This 
suggested that SWAN-1 had at least two functions:  it interacted with Rac GTPases in neurons to 
regulate cell migration, and it interacted with EGL-9 to inhibit HIF-1 transcriptional activity. 
  
Mutation of mbk-1 / DYRK suppresses the swan-1 mutant phenotype: Homologs of SWAN-1 have 
been shown to interact with DYRK dual-specificity tyrosine-phosphorylation regulated kinases in 
yeast, zebrafish, and mammalian systems (HO et al. 2002; MAZMANIAN et al. 2010; SKURAT and 
DIETRICH 2004).  We hypothesized that swan-1 could interact with a DYRK homolog to regulate 
HIF-1 transcriptional activity. To test this, we used bacterially-mediated RNAi to knock down the 
expression of mbk-1, hpk-1 and E02H4.3, three C. elegans genes homologous to mammalian DYRK 
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genes.  As shown in Figure 7A, mbk-1 RNAi suppressed Pnhr-57::GFP expression in 
swan-1(ok267), vhl-1(ok161) double mutants.  However, mbk-1 RNAi did not inhibit expression of 
the reporter in egl-9 mutant animals (Figure 7B).  We obtained similar results using the 
mbk-1(pk1389) loss-of-function mutation (Figure 7C). The mbk-1 deletion allele also inhibited 
Pnhr-57::GFP expression in swan-1(ok267) animals expressing the hif-1(P621G) transgene (Figure 
7D). 
We next asked whether mbk-1 contributed to swan-1-mediated P. aeruginosa PAO1 resistance.  
As shown in Figure 7E and Table S4, mbk-1(pk1389) completely suppressed the PAO1 fast killing 
resistance phenotype in swan-1(ok267), vhl-1(ok161) double mutant animals. Further, mbk-1(pk1389) 
reduced PAO1 resistance in the swan-1(ok267), hif-1(P621G) genetic background, as assayed by two 
independently isolated hif-1(P621G) transgenic lines (Figure 7F and Table S8).  Interestingly, egl-9, 
mbk-1 double mutants are highly resistant to fast killing (table S9).  Thus, in assays of Pnhr-57::GFP 
or P. aeruginosa PAO1 fast killing, the mbk-1 mutation suppresses the swan-1, vhl-1 double mutant 
phenotype, but not the egl-9 loss-of-function phenotype. 
 
DISCUSSION 
 
HIF-1 protects C. elegans from P. aeruginosa PAO1 fast killing: Mutations, alone or in combination, 
that dramatically increase HIF-1-mediated gene expression can protect C. elegans from P. aeruginosa 
PAO1 fast killing.  Prior studies had discovered that loss-of-function mutations in egl-9 conferred 
resistance to P. aeruginosa PAO1 fast killing and to cyanide poisoning, but the role of hif-1 had not 
been investigated (DARBY et al. 1999; GALLAGHER and MANOIL 2001). Here, we establish that the 
resistance of egl-9 mutants to this pathogen is dependent upon hif-1 function (Figure 1A).  EGL-9 is 
a bifunctional protein, and it regulates both HIF-1 protein stability and HIF-1 transcriptional activity 
(SHAO et al. 2009; SHEN et al. 2006).  Interestingly, we find that stabilization of HIF-1 protein is not 
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sufficient to protect C. elegans from P. aeruginosa fast killing, but mutations that disable both EGL-9 
pathways confer resistance. We propose that over-expression of HIF-1 targets beyond a threshold 
level protects C. elegans from the cyanide produced by P. aeruginosa PAO1. 
Hydrogen cyanide is an inhibitor of cytochrome c oxidase, and it is a potent toxin. The cyanide 
produced by P. aeruginosa in cystic fibrosis patients is recognized as a clinically important virulence 
factor (ANDERSON et al. 2010). Cyanide inhibits cytochrome c oxidase, severely disabling ATP 
synthesis through oxidative phosphorylation.  Interestingly, egl-9 mutant animals are also resistant 
to hydrogen sulfide, and H2S is also a cytochrome c oxidase inhibitor (BUDDE and ROTH 2010; 
COOPER and BROWN 2008). A parsimonious explanation is that persistent over-expression of HIF-1 
targets protects C. elegans from cyanide or hydrogen sulfide treatments that disable oxidative 
phosphorylation.  These findings introduce an important question: which HIF-1 target genes protect 
C. elegans from P. aeruginosa PAO1 fast killing?  Prior studies have investigated the genes induced 
by short-term moderate hypoxia at 0.1% oxygen for 4 hours at room temperature (SHEN et al. 2005).  
Future studies will examine the changes in gene expression that are common to mutants or mutant 
combinations that activate HIF-1 and confer resistance to P. aeruginosa. 
Increased expression of HIF-1 targets has been shown to protect C. elegans from diverse 
pathogens or stresses (ANYANFUL et al. 2005; BELLIER et al. 2009; BUDDE and ROTH; MEHTA et al. 
2009; TREININ et al. 2003).  Bellier et al. isolated a loss-of-function mutation in egl-9 in a screen for 
mutations that protected C. elegans from pore-forming toxins (BELLIER et al. 2009).  egl-9 mutants 
have also been shown to be resistant to enteropathogenic E. coli E2348/69 (ANYANFUL et al. 2005). 
Additionally, mutations that stabilize HIF-1 or increase expression of HIF-1 targets have been shown 
to increase C. elegans resistance to polyglutamine or beta-amyloid toxicity and heat stress (BELLIER 
et al. 2009; MEHTA et al. 2009; TREININ et al. 2003; ZHANG et al. 2009).  It is not yet known 
whether the same HIF-1 targets mediate all of these resistance phenotypes, but we anticipate that each 
of these functions may require multiple direct and indirect HIF-1 targets.   
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SWAN-1, a novel regulator of HIF-1: SWAN-1 is an evolutionarily conserved WD-repeat protein of 
the AN11 family (YANG et al. 2006). The data presented here show that SWAN-1 represses 
HIF-1-mediated gene expression, but does not control HIF-1 protein levels.  Double mutants that 
carry a loss-of-function mutation in swan-1 and a mutation that stabilizes HIF-1 protein are 
phenotypically similar to egl-9 loss-of-function mutants, as assayed by fertility, egg laying defects, 
over-expression of HIF-1 targets, and resistance to P. aeruginosa fast killing (Figures 1A, 2G, 4A, 4B, 
5A).  Importantly, we show that SWAN-1 forms a complex with EGL-9 (Figure 6A, 6C). 
Collectively, these data suggest that SWAN-1 and EGL-9 interact directly and repress HIF-1 
transcriptional activity.  
The AN11 family is evolutionarily conserved, and comparative studies may provide important 
insights to the roles of these proteins in stress resistance and transcriptional regulation.  Petunia 
AN11 interacts with a MYB family transcription factor, and the human HAN11 gene has been shown 
to partially rescue Petunia an11 mutant phenotype (DE VETTEN et al. 1997).  In human cells, 
zebrafish, and in yeast, AN11 homologs have been shown to form complexes with DYRK kinases 
(HO et al. 2002; MAZMANIAN et al. 2010; SKURAT and DIETRICH 2004). There are five DYRK 
members in mammals: DYRK1A, DYRK1B, DYRK2, DYRK3 and DYRK4 (PARK et al. 2009). Of 
these, DYRK1A has been characterized most extensively, and it is associated with Down Syndrome 
(ALTAFAJ et al. 2001; SHINDOH et al. 1996; SMITH et al. 1997). DYRK1A is a multifunctional 
protein and has more than two dozen of targets or interacting proteins, including GLI1, STAT3, and 
eIF2Bε. (Park et al. 2009). HAN11 was shown to decrease DYRK1A-mediated phosphorylation of 
GLI1 in a HEK293T cell line (MORITA et al. 2006). 
The genetic analyses presented here suggest that in the absence of SWAN-1, MBK-1/DYRK 
activates HIF-1.  Specifically, a loss-of-function mutation in mbk-1 suppresses the swan-1, vhl-1 
double mutant phenotypes, as assayed by expression of HIF-1 target Pnhr-57::GFP reporter and P. 
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aeruginosa PAO1 fast killing. A goal for future studies will be to identify the targets of 
MBK-1/DYRK to better understand how MBK-1 promotes HIF-1 activity in a swan-1, vhl-1 double 
mutant background   
 A long-term goal will be to understand how hypoxia-induced gene expression influences the 
progression of P. aeruginosa infections.  P. aeruginosa can survive in anaerobic environments, and 
the formation of biofilms likely restricts oxygen availability to infected tissues in human patients.  
Our findings in C. elegans suggest that pharmacological inhibitors of the HIF prolyl hydroxylases 
might contribute to combinatorial therapies to protect cells from the cyanide produced by P. 
aeruginosa PAO1. 
 
MATERIALS AND METHODS 
 
Alleles and worm culture: C. elegans were grown at 20ºC using standard methods unless specified 
(BRENNER 1974).  The loss-of-function alleles and transgenic lines used in this study are listed in 
Table S12 and S13. 
 
Mutagenesis: The EMS forward genetic screen was performed as described previously (SHEN et al. 
2006). Briefly, the parental strain carrying Pnhr-57::GFP and vhl-1(ok161) was mutagenized with 
EMS, and the F2 progeny were screened for increased expression of the Pnhr-57::GFP reporter using 
fluorescent stereomicroscopy.  We generated the rhy-1 loss-of-function alleles ia59, ia62, ia63, ia64 
in a screen for Mos1 transposon-mediated mutations that caused Pnhr-57::GFP overexpression. The 
methods for Mos1 mobilization have been described previously (GRANGER et al. 2004; SHAO et al. 
2009) 
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Mapping ia50 to the swan-1 locus: The ia50 mutant allele was out crossed twice to the parental strain 
prior to any further mapping or characterization. Chromosome and interval mapping were performed 
as described previously using single-nucleotide polymorphisms between the Bristol N2 and Hawaiian 
strains(DAVIS et al. 2005). Briefly, the iaIs07 (Pnhr-57::gfp) transgene and the vhl-1(ok161)  
mutation were crossed extensively into the Hawaiian genetic background.  The resulting males were 
crossed to ia50, vhl-1(ok161) double mutant carrying the iaIs07(Pnhr-57::gfp) marker. Fifty F2 
animals exhibiting the vhl-1, ia50 double mutant phenotype and fifty animals exhibiting the vhl-1 
single mutant phenotype (intestinal GFP expression) were picked into separate tubes, and genomic 
DNA was prepared. Analyses of the divergent SNPs showed enrichment of Bristol bands in mutant 
lanes and an enrichment of Hawaiian bands in non-mutant lanes for SNPs lying between -5 and +13 
mu on chromosome V.  For interval mapping, individual self-progeny of F1 hermaphrodites 
(described above) with the ia50, vhl-1 double mutant phenotype were picked into a 96-well plate to 
prepare the genomic DNA, and four SNPs were analyzed (-5, +1, +6, +13) (DAVIS et al. 2005). We 
then used SNP R10D6 (+5.83 mu) and pkP5086 (+6.42 mu) to do three point mapping. 
 
RNA interference: RNAi was performed as previously described (ZHANG et al. 2009). Bacterial 
strains containing RNAi constructs were purchased from Geneservice Ltd., and inserts were validated 
by sequencing. 
 
Fertility assays: Individual L4-stage worms were placed on NGM plates with fresh OP50 bacterial 
food. The worms were transferred onto fresh plates every 12 hours, and the total progeny laid on each 
plate was counted and recorded at each time point. This procedure was continued until the worms 
reached the end of their reproductive capacity.  
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Constructs: To build pSZ18, the bacterial expression vector for EGL-9::MBP, egl-9 cDNA was 
amplified with the primers: 5’GGTGGATCCAAACCAACGGTATCCAGAAC and 
5’GGGATCCGATGTAATACTCTGGGTTTGTGG. The PCR products were cut with BamHI and 
PstI and ligated into the pMal-p2x vector (from New England Biolabs).  For yeast two-hybrid 
experiments, C. elegans cDNA sequences were inserted in to the pGBKT7 and pGADT7 vectors 
from Clonetech.  The sequences encoding the EGL-9 catalytic domain  were cloned into pGBKT7 
(GAL4 DNA-binding domain vector) with primers: egl-9-F: 
CCGGAATTCGGTCTCGCACTAAGCATTCACC and egl-9-R: CGCGGATCCCCGTGGT 
CTCAAAAGTGATCCAAT. This construct didn’t result in detectable autoactivation. To generate the 
pGADT7-swan-1 deletion plasmids (encoding the Gal4AD-SWAN-1 fusion protein), a series of 
fragments (as shown in Figure 6B) were amplified from the swan-1 prey plasmid kindly provided by 
E. Lundquist and described in (YANG et al. 2006). The primer sets are listed in Table S11. 
 
MBP::EGL-9 protein expression: The plasmid was transformed into BL21 (DE3) bacteria, and a 
single colony was inoculated into liquid media and cultured for 16 hours at 37oC. The bacterial 
culture was diluted by 1:200 to 500ml and cultured for 2.5 hours. IPTG was added to a final 
concentration of 1mM. After 4 hours, the bacteria were pelleted and frozen in liquid nitrogen. The 
bacteria were frozen at -80ºC overnight before adding bacterial lysis buffer (50mM Tris PH7.5, NaCl 
150mM, NP-40 0.1%), 0.25mg/ml lysozyme, 0.01mg/ml DNase, and 1x protease inhibitor cocktail. 
After four hours at 4ºC, the lysate was centrifuged at 12000g for 20min and the supernatant was kept 
for further use. 
 
P. aeruginosa fast killing assays: The fast killing assay follows the approach described previously 
(DARBY et al. 1999; GALLAGHER and MANOIL 2001). Briefly, a single P. aeruginosa PAO1 colony 
was inoculated and cultured at 37ºC for 16 hours in 3-5ml HBI broth. The culture was then diluted 
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100-fold. 300μl diluted bacteria was evenly spread on 60mm diameter Petri dishes with 7ml BHI agar. 
To minimize the possibility of animals escaping from the bacterial lawn, bacteria were spread to 
cover the whole plate. The plates were incubated at 37ºC for 24 hours and then cooled to room 
temperature for 30 minutes. Thirty to fifty developmentally synchronized L4-stage C. elegans were 
put on the lawn and incubated at room temperature (22oC).  Lids to the petri plates remained closed 
during this time to keep hydrogen cyanide from evaporating. C. elegans were scored as paralyzed or 
dead if they did not move when the plate was tapped against the microscope stage. Each data point 
represents at least three independent replicate experiments. 
 
Protein blots: The methods for protein blots have been described previously(SHAO et al. 2009). At 
least three biological replicates were analyzed for each experiment. Transgenic strains expressing 
epitope-tagged HIF-1 were used to assay HIF-1 protein levels and each lane of a protein gel included 
lysate from 40 – 100 L4-stage animals. For the Pnhr-57::GFP reporter, we used 5-50 L4 animals. The 
statistical significance of differences was assessed by two-sample paired t-tests or one way ANOVA 
with Bonferroni post test. 
 
Real time PCR: The methods for real time PCR were as described previously(SHAO et al. 2009). At 
least three biological replicates were analyzed for each experiment, and each PCR reaction was 
performed in duplicate.  The statistical significance of differences was assessed by two-sample 
paired t-tests or one way ANOVA with Bonferroni post test. 
 
Yeast two-hybrid assays: The MatchmakerTM GAL4 Two-Hybrid system 3 (Clontech) and yeast strain 
AH109 were used. swan-1 cDNA was fused to prey pGADT7 plasmid and egl-9 catalytic coding 
sequence was fused to bait pGBKT7 plasmid. The transformation was performed as described 
previously (GIETZ et al. 1992; SCHIESTL and GIETZ 1989). The negative controls included the 
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cotransformation of pGADT7-swan-1 plasmids with pGBKT7 (empty vector); the cotransformation 
of pGBKT7-egl-9 and pGADT7; and the cotransformation of pGBKT and pGADT7.  To test for 
interactions, yeast colonies carrying both plasmids (selected on Leu-, Trp- plates) were cultured in 2 
ml Leu-/Trp- liquid SD-medium for 24 hours at 30°C.  Twenty individual colonies were then assayed 
for growth on Ade-/His-/Leu-/Trp- X-α-gal SD-medium plates. Additionally, six Leu+/Trp+ colonies 
were cultured for quantification of the β-galactosidase activity using 
O-nitrophenyl-B-D-galactopyranoside as a substrate. 
 
Co-immunoprecipitation experiments: The C. elegans strain expressing SWAN-1::GFP [transgenic 
array lqEx19 (Pswan-1:: swan-1::gfp)] was kindly provided by Erik Lundquist. C. elegans were 
grown on 100mm enriched media plates with NA22 bacteria, and 0.4ml mixed stage worms were 
harvested. Animals were washed with cold M9 buffer three times and were washed once with worm 
lysis buffer (50mM Tris-HCl PH7.4, 150mM NaCl, 0.5% Triton-X-100, 10% glycerol, 1mM DTT, 
and 1X protease inhibitor cocktail from Roche).  The worm pellet was resuspended in 1.2ml worm 
lysis buffer, and the animals were lysed in a french press (Thermo Electron Corporation) with 1000 
psi pressure three times.  To perform immunoprecipiations, 80μl G-Sepharose beads were washed 
with worm lysate buffer three times for 10 minutes for each and then incubated with 80μl 0.4mg/ml 
GFP antibody (Roche) overnight.  Beads were washed with worm lysis buffer three times for 5 
minutes for each and divided into two 40μl aliquots, each of which was incubated with 600μl of 
SWAN-1::GFP or GFP worm lysate at 4ºC for 4hours.  Beads with either control GFP 
[Pnhr-57::GFP] or SWAN-1::GFP were washed (three times 10 minutes in cold lysis buffer) and 
incubated with MBP::EGL-9. After four hours incubation at 4ºC, beads were washed with worm lysis 
buffer and boiled in 40μl 1xSDS buffer.  The proteins were fractionated by 10% SDS 
polyacrylamide gel electrophoresis, and blots were probed with maltose binding protein rabbit 
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antiserum (from NEB at 1:3000 dilution) or mouse GFP monoclonal antibody (clones 7.1 and 13.1 
from Roche at 1:1000 dilution). 
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TABLE 
Table 1 Mutants of egl-9 or rhy-1 are resistant to P. aeruginosa PAO1 fast killing in a 
hif-1-dependent manner 
Strains 
Survival rate 
after 4 hours 
Total 
animals 
Experimental 
replicates 
N2 3% 171 5 
rhy-1(ok1402) 93% 178 5 
rhy-1(ok1402) hif-1(ia04) 0% 142 4 
egl-9(sa307) 100% 177 3 
egl-9(ia60) 100% 91 4 
rhy-1(ia58) 100% 67 2 
rhy-1 (ia59) 100% 123 3 
rhy-1 (ia63) 99% 143 3 
rhy-1 (ia64) 100% 112 2 
rhy-1 (ia62) 95% 71 2 
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FIGURE LEGENDS 
Figure 1: egl-9-mediated resistance to Pseudomonas aeruginosa PAO1 fast killing is mediated by 
hif-1 and requires multiple egl-9 functions:  A.  Percent C. elegans survival over time on P. 
aeruginosa PAO1.  Wild-type N2 and hif-1 mutants exhibit similar sensitivity to fast killing (>50% 
dead by 40 minutes), but 100% of animals carrying a strong loss-of-function mutation in egl-9 
survived after 2 hours. The P. aeruginosa resistance phenotype conferred by egl-9 (sa307) was 
suppressed by the hif-1 (ia04) strong loss-of-function allele.  B.  Stabilization of HIF-1 protein was 
not sufficient to confer resistance to P. aeruginosa PAO1 fast killing.  The survival curves for 
strains expressing epitope-tagged HIF-1 or stabilized HIF-1(P621G) were similar to that of the 
wild-type strain.  Three independently generated transgenic strains expressing HIF-1(P621G) were 
assayed.  Each experiment has been repeated at least three times with 30-50 animals for each strain. 
The error bars represent standard errors.  These data are also presented in tabular format in 
Supplemental Materials (Table S1 and S3). 
 
Figure 2 Characterization of the ia50 mutation:  The ia50 allele was isolated in a genetic screen for 
mutations that increased expression of Pnhr-57::GFP in animals expressing stabilized HIF-1.  A – F.  
Fluorescent images are shown in A, B, C, and the corresponding DIC images are in D, E, F.  A, D. 
Wild-type animals express the reporter a very low levels.  B, E. In animals carrying the vhl-1 (ok161) 
strong loss-of-function mutation, HIF-1 protein is stable, and the reporter is expressed throughout the 
intestine.  C, F. ia50, vhl-1(ok161) double mutants express the reporter at higher levels and in more 
tissues, including the excretory cell and the hypodermis.   G.  Like animals carrying strong 
loss-of-function mutations in egl-9, the ia50, vhl-1(ok161) double mutants and have fewer progeny 
than wild-type animals.   
 
Figure 3: ia50 is a loss of function mutation in the swan-1 gene: A.  Genetic mapping of the ia50 
mutation. Three-point mapping with the indicated single nucleotide polymorphisms placed ia50 at 
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+5.67 mu on chromosome V.  Injection of a pool of 3 cosmids in the region (F20G2, F53C11, and 
F55B12) restored the ia50 homozygous mutants to wild-type phenotype, as assayed by Pnhr-57::GFP 
expression.  This region includes the swan-1 gene.  swan-1 (ok267) is a deletion mutation.  B. 
ia50 mutants carry a point mutation at 3’ end of intron 2 of swan-1.  C. Depletion of swan-1 by 
bacterially-mediated RNAi increased expression of the Pnhr-57::GFP reporter, as assayed by protein 
blots. RNAi of swan-2 had no effect on Pnhr-57::GFP expression.  In control experiments, RNAi for 
the related swan-2 gene did not alter Pnhr-57::GFP levels.  D.  The swan-1 (ok267) mutation 
increased expression of the Pnhr-57::GFP reporter in vhl-1 (ok161) animals, and this phenotype was 
suppressed by the hif-1 (ia04) strong loss-of-function mutation.  Pnhr-57::GFP levels were assayed 
by protein blots, and the error bars represent standard errors. **: P<0.01 
 
Figure 4:  Loss-of-function mutations in swan-1 increase expression of additional HIF-1 target 
genes, but do not alter HIF-1 protein levels: A, B. The expression levels of two HIF-1 target genes, 
F22B5.4 and K10H10.2, were assayed by quantitative RT-PCR.  HIF-1 protein was stabilized by the 
vhl-1 (ok161) mutation.  For both genes assayed, the swan-1 (ok267) mutation increased mRNA 
expression, and this phenotype was suppressed by the hif-1 (ia04) loss-of-function mutation.  The 
bars represent means from 3 independent replicates, and error bars reflect standard errors.  C.  The 
swan-1 (ok267) mutation did not change HIF-1 protein levels, as assayed by protein blots. Three 
biological replicates were done. n. s.: not significant; ** p<0.01. 
 
Figure 5:  The swan-1 (ok267) vhl-1 (ok161) double mutant is more resistant to P. aeruginosa 
PAO1 fast killing than either single mutant: A, B.  Percent C. elegans survival over time on P. 
aeruginosa PAO1.  A. vhl-1(ok161), swan-1 double mutant animals are resistant to the fast killing 
by P. aeruginosa, PAO1 (~40% survival after 2 hours). Animals the vhl-1(ok161) or swan-1(ok267) 
single mutations are not resistant.  B  The swan-1 (ok267) mutation increases resistance to P. 
aeruginosa PAO1 fast killing in animals expressing stabilized HIF-1 protein.  Each point on the line 
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graph represents a mean from at least 3 replicate experiments.  The error bars represent standard 
errors.  These data are presented in tabular format in Supplemental Materials (Table S4 and S7). 
 
 
Figure 6:  SWAN-1 binds to EGL-9: A. In yeast two-hybrid assays, SWAN-1 interacts with EGL-9, 
as assayed by growth on Ade-/His-/Leu-/Trp- media and by β-galactosidase activity with 1x, 10x, 100x, 
1000x dilution from left to right.  In control experiments, yeast with the bait and prey vectors 
without inserts (pGADT7 and pGBKT7) do not grow in these conditions.  B  SWAN-1 deletions 
were assayed for interaction with EGL-9 in the yeast two-hybrid system. Seven evolutionary 
conserved WD domains, one degenerated WD (WD?) domain and the C-terminal domain (CTD) are 
indicated in the boxes (YANG et al. 2006). β-galactosidase activity and growth were scored in at least 
3 replicates for each construct with the empty vector pGADT7 as a negative control (++: p<0.0001; +: 
0.000<p<0.05, -: p>0.05).  The amino-terminal domain of SWAN-1 containing 3 WD repeats 
interacted strongly with EGL-9.  These data are detailed further in Table S10. C. In additional 
interaction studies, the SWAN-1::GFP protein fusion (YANG et al. 2006) or GFP was 
immunoprecipitated from transgenic worms and then incubated with bacterially-expressed EGL-9 
fused to maltose binding protein (MBP::EGL-9).  MBP::GFP co-purified with SWAN-1::GFP (lanes 
5 – 8) and is compared to the negative controls using GFP (lanes 1 - 4). 
 
Figure 7:  Genetic interactions between swan-1 and mbk-1 / DYRK to regulate Pnhr-57::GFP 
expression and resistance to P. aeruginosa fast killing:  A, B.  Bacterially mediated RNAi was 
used to decrease expression of individual DYRK homologs in C. elegans, and the effects on the 
Pnhr-57::GFP reporter.  The bars show mean values from 3 replicate experiments; error bars 
represent standard errors. ** p<0.01.  A.  In swan-1 (ok267), vhl-1 (ok161) double mutants, mbk-1 
RNAi significantly decreased expression of the reporter, but RNAi for the other DYRK homologs 
does not change Pnhr-57::GFP levels relative to the L4440 empty vector control.  B.  In egl-9 
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(sa307) animals, RNAi for the DYRK homologs tested had no effect on Pnhr-57::GFP.  C, D.  The 
mbk-1 (pk1389) deletion mutation suppressed Pnhr-57::GFP expression in swan-1(ok267) 
vhl-1(ok161) double mutant animals (C) and in swan-1 (ok267) animals expressing stabilized 
HIF-1(P621G) protein (D).  E, F.  The mbk-1 (pk1389) mutation suppressed resistance to P. 
aeruginosa, PAO1 in swan-1 (ok267) animals.  In these experiments, HIF-1 protein stabilized by 
either the vhl-1 (ok161) loss-of-function mutation (E) or the HIF-1(P621) stabilizing mutation (F). 
Each experiment has been repeated at least three times with 30-50 animals for each strain. The error 
bars represent standard errors. *: p<0.05; **: p<0.01. These data are presented in tabular format in 
Supplemental Materials (table S4 and S8) 
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SUPPLEMENTAL MATERIALS  
Tables 
Table S1. Percentage of survival of wildtype N2, hif-1(ia04), egl-9(sa307), and egl-9(sa307) hif-1(ia04) on 
PAO1 bacteria lawn over time 
 0min 20min 40min 60min 90min 120min 
Replicates/ total 
animals 
N2 100% 84%±4% 16%±6% 9%±2% 0% 0% 3/102
hif-1(ia04) 100% 90%±4% 24%±16% 6%±7% 0% 0% 3/116
egl-9(sa307) 100% 100% 100% 100% 100% 100% 3/109
egl-9(sa307) 
 hif-1(ia04) 100% 93%±4% 19%±8% 4%±5% 1%±2% 0% 3/107
 
 
Table S2. Percentage of survival of N2, hif-1(ia04), egl-9(sa307), and egl-9(sa307) hif-1(ia04), rhy-1(ok1402) 
double mutant after four hours on MP507*  
Genotype Average Replicates/ total animals 
N2 96.9%±4% 2/74
egl-9(sa307) 100.0% 2/70
egl-9(sa307) 
hif-1(ia04) 98.7%±2% 3/116
rhy-1(ok1402) 97.3%±2% 4/150
* MP507 a P. aeruginosa strain carrying a mutation in hcnC gene, which encodes a subunit of hydrogen 
cyanide synthase (GALLAGHER and MANOIL 2001) 
 
Table S3.  Percentage of survival of N2 and hif-1 transgenic strains on bacteria PAO1 lawn over time 
  0min 20min 40min 60min 90min 120min
Replicates 
/ total animals 
N2 100% 80%±8% 20%±7% 4%±2% 0% 0% 3/128 
iaIs28* 100% 68%±20% 13%±6% 0% 0% 0% 3/113 
iaIs32# 100% 85%±9% 34%±22% 3%±3% 0% 0% 3/117 
iaIs33# 100% 58%±19% 5%±3% 0% 0% 0% 3/114 
iaIs34# 100% 67%±17% 5%±2% 0% 0% 0% 3/113 
*: hif-1(+) transgenic line; #: hif-1(P621G) transgenic lines 
 
Table S4. Percentage of survival of swan-1(ok267), vhl-1(ok161), vhl-1(ok161) swan-1(ok267) double and 
vhl-1(ok161) swan-1(ok267) mbk-1(pk1389) triple mutant on bacteria PAO1 lawn 
 0min 20min 40min 60min 90min 120min 
Replicates/ 
total 
animals 
swan-1(ok267) 100% 74%±6% 13%±3% 2%±2% 2%±2% 2%±2% 4/156
vhl-1(ok161) 100% 0% 0% 0% 0% 0% 3/111
swan-1(ok267), 
 vhl-1(ok161) 100% 93%±5% 56%±2% 39%±3% 37%±3% 36%±3% 3/117
swan-1(ok267), 
 vhl-1(ok161), 
mbk-1(pk1389) 100% 16%±14% 0% 0% 0% 0% 4/153
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Table S5. Molecular information of new rhy-1 alleles 
Alleles Left flanking sequence right flanking sequence MOS1 landed in 
ia59 Gaaactcgatg tattggatatc second exon 
ia62 Aaatgcattta ttcctgatact first exon 
ia63 Acacggcagta ttccgatctgt third exon 
ia64 Tatctccttca tatccagttgt fourth exon 
 
Table S6. Percentage of survival of swan-1(ok267), vhl-1(ok161), vhl-1(ok161) swan-1(ok267) double and 
vhl-1(ok161) swan-1(ok267) hif-1(ia04) triple mutant after four hours on bacteria lawn PAO1 or MP507  
 PAO1 P507 
 Survival rate Replicates/ total animals Survival rate 
Replicates/ total 
animals 
swan-1(ok267) 0% 4/194 100% 3/115
vhl-1(ok161) 0% 4/201 92%±5% 3/130
swan-1(ok267) 
vhl-1(ok161) 45%±4% 5/251 98%±1% 4/153
swan-1(ok267) hif-1(ia04) 
vhl-1(ok161) 0% 4/220 100% 4/173
 
Table S7. Percentage of survival of N2, swan-1(ok267), hif-1(P621G) transgenic strains, and swan-1(ok267) 
with transgene hif-1(P621G) on bacteria PAO1 lawn over time 
  0min 20min 40min 60min 90min 120min 
Replicates 
/ total animals 
N2 100% 94%±4% 54%±13% 17%±3% 4%±3% 0% 4/145
swan-1(ok267) 100% 89%±5% 50%±12% 16%±5% 8%±5% 7%±5% 4/147
iaIs32# 100% 95%±5% 52%±13% 10%±4% 0% 0% 4/160
swan-1(ok267, 
 iaIs32# 100% 100% 99%±1% 96%±2% 95%±3% 95%±3% 4/153
iaIs33# 100% 94%±5% 10%±3% 2%±2% 0% 0% 3/121
swan-1(ok267), 
iaIs33# 100% 100% 100% 100% 100% 100% 4/156
#: hif-1(P621G) transgenic lines 
 
Table S8. Percentage of survival of mbk-1(pk1389), swan-1(ok267) with hif-1(P621G) transgene, and 
swan-1(ok267) mbk-1(pk1389) with transgene hif-1(P621G) on bacteria PAO1 lawn over time 
 0min 20min 40min 60min 90min 120min 
Replicates
/ total 
animals 
mbk-1(pk1289) 100% 69%±9% 24%±13% 2%±2% 0% 0% 3/107
iaI32#  
swan-1(ok267) 100% 97%±2% 96%±3% 95%±3% 95%±3% 94%±3% 5/185
iaIs33#  
swan-1(ok267) 100% 100% 99%±1% 99%±1% 99%±1% 99%±1% 5/178
iais32# 
swan-1(ok267) 
 mbk-1(pk1389) 100% 89%±7% 35%±10% 18%±7% 16%±6% 16%±6% 5/194
iaIs33#  
swan-1(ok267)  
mbk-1(pk1389) 100% 97%±1% 42%±14% 22%±12% 20%±10% 20%±10% 5190
#: hif-1(P621G) transgenic lines 
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Table S9. Percentage of survival of mbk-1(pk1389), egl-9(sa307), egl-9(sa307) mbk-1(pk1389) double mutant, 
rhy-1(ia59) mbk-1(pk1389) double mutant on bacteria PAO1 lawn over time 
 0min 20min 40min 60min 90min 120min 
Replicates/ 
total 
animals 
mbk-1(pk1389) 100% 69%±9% 24%±13% 2%±2% 0% 0% 3/107
egl-9(sa307) 100% 100% 100% 100% 100% 100% 3/109
egl-9(sa307) 
 mbk-1(pk1389) 100% 100% 100% 100% 100% 100% 3/110
rhy-1(ia59) 
 mbk-1(pk1389) 100% 100% 100% 99%±1% 99%±1% 97%±1% 3/92
 
Table S10. Protein-protein interaction between SWAN-1 deletions and EGL-9 in yeast two-hybrid assay. 
Bait 
protein 
Prey protein Growth on 
Selective medium(a)
β-Galctosidase 
Activity  
(Mean±SD, n=6) 
Fold increase 
in β-Gal 
activity (b) 
EGL-9 SWAN-1: full length 
(1-388aa) 
+ 0.216±0.059 1.83 
EGL-9 SWAN-1: 
ATG-WD5(1-260aa) 
++ 0.365±0.076 3.09 
EGL-9 SWAN-1: ATG-WD3 
(1-196aa) 
++ 0.494±0.058 4.19 
EGL-9 SWAN-1: WD3-CTD 
(162-388aa) 
+ 0.219±0.046 1.85 
EGL-9 SWAN-1: WD3-WD5 
(162-260aa) 
+ 0.224±0.032 1.90 
EGL-9 SWAN-1: WD5-CTD 
(227-388) 
- 0.131±0.039 1.11 
(a). Yeast colonies on selective medium (SD medium lacking tryptophan, leucine, histidine, and adenine adding 
X-α-gal) within 3 days (++), 5 days (+) or no growth after 7 days (-). 
(b). Fold increase over β-Galctosidase activity units of the strains expressing both empty prey and bait vectors. 
 
Table S11 Primers for making swan-1 deletion constructs 
Constructs Primer pairs* 
Full length swan-F1/ Swan-Rctd        
N-terminus-WD5 swan-F1/ Swan-Rwd5 
N-terminus-WD3 swan-F1/ Swan-Rwd3 
WD3-WD5 Swan-WD3F/ Swan-Rwd5 
WD3-C-terminus Swan-WD3F/ Swan-Rctd 
WD5-C-terminus Swan-WD5F/ Swan-Rctd 
* Swan-F1: CCGGAATTCATGGCTACCAATGGTCACGCAGTG 
Swan-WD3F: CCGGAATTCTCACAATATGGATCAGCTTTG 
Swan-WD5F: CCGGAATTCTTTGCTAAAATCAATGGCGGT 
Swan-Rctd: CGCATCGATAACTCGAAGAATCTCAAGAGT 
Swan-Rwd5: CGCATCGATTTCATAGACAATTGTCGAGTG 
Swan-Rwd3: CGCATCGATCTCAACATCATAAATTGTGCG 
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Table S12 alleles that have been used in this study 
Genes  Alleles Description References 
hif-1 ia04 Loss of function (JIANG et al. 2001) 
vhl-1 ok161 Loss of function (EPSTEIN et al. 2001) 
sa307 Loss of function (DARBY et al. 1999) 
egl-9 ia60 Loss of function (SHAO et al. 2009) 
rhy-1 ok1420 Loss of function (SHEN et al. 2006) 
ok267 Loss of function (YANG et al. 2006) 
swan-1 ia50 Loss of function This study 
mbk-1 pk1389 Loss of function (RAICH et al. 2003) 
 
Table S13 Transgenic events  
Transgenic lines Description References 
iaIs28* Phif-1::hif-1::HA-MYC-STREP
iaIs32* Phif-1::hif-1(P621G)::MYC 
iaIs33* Phif-1::hif-1(P621G)::MYC 
iaIs34* Phif-1::hif-1(P621G)::MYC 
(SHAO et al. 2009; ZHANG et al. 
2009) 
iaIs07* Pnhr-57::GFP (SHEN et al. 2006) 
lqEx19# Pswan-1::swan-1::GFP (YANG et al. 2006) 
* unc-119 was used as coinjection marker 
# lin-15 was used as coinjection marker (Yang, 2006, #56) 
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Figure 
 
 
Figure S1  Knockdown unc-115, mig-2, ced-10 by RNAi or mutation does not change hif-1 
target GFP expression in vhl-1, vhl-1 swan-1, or egl-9 mutant animals 
A. mutation of unc-115 does significantly change Pnhr-57::GFP expression. B. Knockdown 
ced-10 or mig-2 by RNAi does not alter Pnhr-57::GFP expression. C. loss of function 
mutation at unc-115 or mig-2 does not obviously change Pnhr-57::GFP expression. D. 
mutation of mig-2 or unc-115 does not dramatically suppress Pnhr-57::GFP expression in 
egl-9 mutant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     111
References 
 
DARBY, C., C. L. COSMA, J. H. THOMAS and C. MANOIL, 1999 Lethal paralysis of Caenorhabditis 
elegans by Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 96: 15202-15207. 
EPSTEIN, A. C., J. M. GLEADLE, L. A. MCNEILL, K. S. HEWITSON, J. O'ROURKE et al., 2001 C. 
elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF 
by prolyl hydroxylation. Cell 107: 43-54. 
GALLAGHER, L. A., and C. MANOIL, 2001 Pseudomonas aeruginosa PAO1 kills Caenorhabditis 
elegans by cyanide poisoning. J Bacteriol 183: 6207-6214. 
JIANG, H., R. GUO and J. A. POWELL-COFFMAN, 2001 The Caenorhabditis elegans hif-1 gene encodes 
a bHLH-PAS protein that is required for adaptation to hypoxia. Proc Natl Acad Sci U S A 98: 
7916-7921. 
RAICH, W. B., C. MOORMAN, C. O. LACEFIELD, J. LEHRER, D. BARTSCH et al., 2003 Characterization 
of Caenorhabditis elegans homologs of the Down syndrome candidate gene DYRK1A. 
Genetics 163: 571-580. 
SHAO, Z., Y. ZHANG and J. A. POWELL-COFFMAN, 2009 Two distinct roles for EGL-9 in the 
regulation of HIF-1-mediated gene expression in Caenorhabditis elegans. Genetics 183: 
821-829. 
SHEN, C., Z. SHAO and J. A. POWELL-COFFMAN, 2006 The Caenorhabditis elegans rhy-1 gene 
inhibits HIF-1 hypoxia-inducible factor activity in a negative feedback loop that does not 
include vhl-1. Genetics 174: 1205-1214. 
YANG, Y., J. LU, J. ROVNAK, S. L. QUACKENBUSH and E. A. LUNDQUIST, 2006 SWAN-1, a 
Caenorhabditis elegans WD repeat protein of the AN11 family, is a negative regulator of Rac 
GTPase function. Genetics 174: 1917-1932. 
ZHANG, Y., Z. SHAO, Z. ZHAI, C. SHEN and J. A. POWELL-COFFMAN, 2009 The HIF-1 
hypoxia-inducible factor modulates lifespan in C. elegans. PLoS One 4: e6348. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     112
CHAPTER 4. GENERAL CONCLUSION 
 
SIGNIFICANCE OF THE STUDY 
Hypoxia-inducible transcription factors (HIF) have multiple roles in animal development, 
immune defense, tumorgenesis and other ischemia-related diseases. Understanding the regulation of 
HIF(s) will not only shed light on the mechanisms of normal development and pathogenesis, but also 
provide clues for developing drugs to treat those diseases. C. elegans has proven to be a powerful 
genetic model for studying HIF-1(EPSTEIN et al. 2001; JIANG et al. 2001; POWELL-COFFMAN et al. 
1998; SHEN et al. 2005; SHEN et al. 2006) .   
 
GOALS OF THE STUDY 
The long-term goal of this study is to explore the HIF-1 regulatory networks using C. elegans as 
a model. Using molecular and forward genetics approaches, this study aims to understand the 
molecular mechanism underlying regulation of HIF-1 transcriptional activity by EGL-9.  
 
IMPACTS OF THE STUDY 
As a model system, C. elegans allows us to understand PHD/HIF function in vivo. One major 
disadvantage of studying PHD/HIF in mammals is that deficiency of the major genes (Phd2, Hif-1α 
or Hif-2α) in the family is lethal, so most findings in mammals are from cell or tissue culture systems. 
However, neither egl-9 nor hif-1 is essential for C. elegans in normal culture conditions. Taking 
advantage of this, Shen et al. identified hif-1-dependent hypoxia induced genes in vivo (SHEN et al. 
2005). The identification of hif-1 target genes advances our study of the HIF-1 regulatory pathways. 
A second advantage of our system is that the hif-1 target GFP reporter allows us to visualize hif-1 
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activity in live animals (SHEN et al. 2006). The central advantage of this model system is that C. 
elegans is amendable to lots of genetic approaches to discover genes that regulate hypoxia responses.  
Through analyzing the expression of hif-1 target GFP reporter and endogenous hif-1 targets, 
Shen et al. previously found that in addition to regulating HIF-1 protein stability, EGL-9 also played 
a role in repressing HIF-1 transcriptional activity (SHEN et al. 2006). Interestingly, studies in 
mammalian cell culture also found that PHD2 repressed HIF activity (OZER et al. 2005; TO and 
HUANG 2005). However, the molecular mechanisms remain to be demonstrated. 
EGL-9 and HIF-1 have multiple roles in stress and pathogen resistance. For example, loss-of 
function of mutations of egl-9 were found to confer resistance to Pseudomonas earuginosa PAO1 fast 
killing (DARBY et al. 1999; GALLAGHER and MANOIL 2001). A recent study from Roth’s group 
found that animals with egl-9 or vhl-1 mutants were resistant to hydrogen sulfide (BUDDE and ROTH 
2010). Like hydrogen cyanide, hydrogen sulfide inhibits cytochrome c oxidase (COOPER and BROWN 
2008). Hydrogen cyanide or hydrogen sulfide is potential lethal to animals. Our current hypothesis is 
that both compounds kill C. elegans by inhibiting oxidative phosphorylation. hif-1 is required for 
resistance of egl-9 or vhl-1 mutant to hydrogen sulfide (BUDDE and ROTH 2010). However, the 
molecular basis of the resistance to P. earuginosa PAO1 is not known.    
In this dissertation I provide insight into the HIF-1 transcriptional activity regulation by EGL-9 
through multiple approaches including forward and reverse genetic screens, site-directed mutagenesis, 
hypoxia and pharmacological inhibitor treatments. I found that EGL-9 was a bifunctional protein. It 
regulates HIF-1 stability through hydroxylating the conserved pro621 in LXXLAP motif (EPSTEIN 
et al. 2001), and it suppresses expression of HIF-1 targets with little requirement of the hydroxylase 
activity (Chapter 2).  We also identified SWAN-1 as a novel hif-1 negative regulator acting in 
concert with EGL-9 to regulate hif-1 target gene expression without changing HIF-1 protein levels. 
Finally, I also found that hif-1 was required for the resistance of egl-9 mutants to P. earuginosa PAO1 
(Chapter 3). These findings broaden our understanding of the regulation and function of HIF-1. 
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MAJOR FINDINGS 
EGL-9 is the key regulator of HIF-1. In C. elegans and in mammals, HIF induces the expression 
of HIF proline hydroxylases EGL-9/PHDs, establishing a negative feedback loop that reduces HIF 
activity (EPSTEIN et al. 2001; SHEN et al. 2005). The catalytic functions of EGL-9/PHD enzymes are 
of central importance in normal development, homeostasis and disease states and have been studied 
intensively (BOULAHBEL et al. 2009; KAELIN and RATCLIFFE 2008; PANCHISION 2009). However, 
the vhl-1-independent functions of this class of proteins are less well understood.  In Chapter 2 of 
this dissertation, I found that (i) mutation at the EGL-9 target HIF-1 P621 stabilized HIF-1 protein 
through inactivation of the egl-9/vhl-1 pathway, but it did not abrogate EGL-9-mediated inhibition of 
HIF-1 target gene expression (Figure 2B, 2C); (ii) suppression of EGL-9 catalytic activity by hypoxia 
or treatment with DIP released HIF-1 from VHL-1-mediated destabilization, but did not fully 
eliminate egl-9 functions (Figure 3A, 3B); (iii) a mutation at the His487 of EGL-9 that is required for 
iron binding abolished HIF-1 destabilization, but it did not eliminate all EGL-9-mediated repressions 
of HIF-1 transcriptional activity (Figure 4C, 4D, 4E); (iv) a complete deletion of an evolutionarily 
conserved MYND zinc finger domain in EGL-9 did not result in a significant change in HIF-1 protein 
levels, or in expression of hif-1 targets (Figure 6); (v) with the exception of the MYND deletion allele, 
all of the egl-9 mutant alleles tested dramatically increased both HIF-1 protein and expression of hif-1 
targets with little variation (Figure 5, Figure 6); There was a correlation between levels of 
Pnhr-57::GFP expression and the severity of egg laying defects in egl-9 mutants. (vi) sequencing 19 
egl-9 cDNAs, I found nine different mRNA isoforms with different abundances (Figure S3). The 
most abundant isoform egl-9a is the most important transcript, which is supported by that expression 
of egl-9a can fully rescue a severe loss of function egl-9 mutant as assayed by quantitating expression 
of hif-1 target genes. 
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 In Chapter 3, I reported seven major findings. (i) The egl-9 (sa307) strong loss-of-function 
mutation has been shown to protect C. elegans from fast killing of the P. aeruginosa PAO1 pathogen 
(DARBY et al. 1999; GALLAGHER and MANOIL 2001) (Figure 1A).  To better understand the egl-9 
loss-of-function phenotype and the genetic basis for resistance to P. aeruginosa PAO1 fast killing, I 
asked whether the resistance to PAO1 fast killing exhibited by egl-9 mutants required hif-1 function.  
As shown in Figure 1A, the hif-1(ia04) loss-of-function allele totally suppressed the egl-9-mediated 
resistance phenotype. (ii) Since we know egl-9 regulates HIF-1 protein stability and the 
transcriptional activity (SHAO et al. 2009; SHEN et al. 2006), I asked whether the stabilization of 
HIF-1 protein by expression of stabilized hif-1(P621G) transgene or mutation of vhl-1 was sufficient 
to confer PAO1 resistance. Interestingly, I found that stabilization of HIF-1 was not sufficient to 
increase the resistance (Figure 1B). (iii) In order to identify genes that regulate HIF-1 in a vhl-1 
independent manner and are required to protect C. elegans from PAO1 fast killing, we performed 
forward genetic screens using wildtype or stabilized HIF-1 background (vhl-1 mutant).  In a Mos1 
transposon-mediated screen, I isolated multiple egl-9 and rhy-1 alleles. All egl-9 and rhy-1 mutant 
alleles tested were resistant to PAO1 fast killing (Table 1). (iv) In an EMS (ethyl methanesulfonate) 
screen, colleagues in the lab isolated ia50, which turned out to be a swan-1 loss of function mutant 
allele. swan-1 encodes a WD-repeat protein belonging to AN11 family (YANG et al. 2006). I found 
that SWAN-1 negatively regulated expression of hif-1 target genes, with little effect on HIF-1 protein 
levels (Figure 2, 3 and 4). (v) Animals carrying a swan-1 mutation and stabilized HIF-1 mimicked 
egl-9 mutant phenotypes as assayed by regulation of HIF-1, brood size and resistance to PAO1 fast 
killing (Figure 2, 3, 4 and 5). (vi) The similar phenotype between the egl-9 mutant and the swan-1 
vhl-1 double mutant inspired us to ask if SWAN-1 bound to EGL-9. In coolaboration with Qi Ye, we 
found that SWAN-1 bound to EGL-9 in a yeast-two-hybrid and by coimmunoprecipitation (Figure 6). 
(vii) Homologs of SWAN-1 have been shown to interact with DYRK1 kinases in yeast and 
mammalian systems (HO et al. 2002; SKURAT and DIETRICH 2004).  We hypothesized that swan-1 
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would interact with a DYRK1 homolog to regulate HIF-1 transcriptional activity. Indeed, I found that 
mutation of mbk-1, a DYRK1 encoding gene, suppressed the swan-1 mutant phenotypes in the 
regulation of HIF-1 transcriptional activity or PAO1 resistance (Figure 7). 
 
LIMITATIONS OF THE STUDIES 
A major disadvantage of using C. elegans to study hypoxia signaling pathways is that there are 
some molecules or pathways don’t exist in C. elegans. For example, FIH (factor inhibiting HIF), a 
negative HIF regulator, is found in many species. However, there is no clear FIH encoding gene 
identified in C. elegans. In this case, using C. elegans system would directly not help to understand or 
develop pharmocological treatments for this specific pathway related diseases. 
 A second limitation in the studies is that we have used a lot transgenic analysis. The major 
concerns with regard to using transgene are the isoform and levels of expression of transgenes. The 
copy number of a transgene is usually much more than the endogenous copy number, two for most 
genes. For integrated transgenes, the expression level is also dependent on the site of the integration. 
The expression is usually much higher if the transgene inserted in constitutively active regions than in 
silented regions. Additionally, the genomic DNA and cDNA fusion constructs that we used in the 
studies (hif-1 and egl-9 transgene) only encodes the specific splicing isoforms. The function of these 
transgenes may be different from the endogenous genes due to the isoform specificity and ectopic tag 
that fused to the transgenes. 
A third limitation in the studies is that I only used a limited number of hif-1 targets. In most 
assay, I use Pnhr-57::GFP as a HIF-1 activity reporter. This reporter may also be regulated by other 
transcription factors. Although I also looked at expression of other hif-1 targets, only limited number 
of hif-1 targets was analyzed. The fact that HIF-1 transcription activity may be regulated by a target 
specific mechanism will lead to failure to identify some regulatory components in our mutagenesis 
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screens. Additionally, all the conclusions I made for HIF-1 activity are based on maximum of three 
hif-1 targets. More hif-1 targets should be included to make reliable conclusions. 
We performed our assay using whole animals, by which we can not tell tissue specificity of the 
HIF-1 activity. It is especially important when we think about the biological function of HIF-1. For 
example, it would be interested if we know where overexpression of hif-1 targets confers resistance to 
P. aeruginosa PAO1.   
Additionally, the protein protein interaction assay we did is yeast or cell free system. We don’t 
have any evidence that shows that in C. elegans EGL-9 and SWAN-1 bind to each other. It would be 
really interesting to see if EGL-9 and SWAN-1 interact in vivo. 
 
QUESTIONS REMAIN TO BE ANSWERED 
How does EGL-9 regulate HIF-1 transcriptional activity? In C. elegans and in mammals, 
EGL-9/PHD2 has been shown to regulate both HIF-1 protein stability and transcriptional activity 
(EPSTEIN et al. 2001; OZER et al. 2005; SHEN et al. 2006; TO and HUANG 2005). Ozer et al. found 
that in HeLa cells, the tumor suppressor ING4 bound to PHD2 at the HRE (hypoxia response 
element), and repressed HIF-1 transcription activity (TO and HUANG 2005). However, the 
semi-quantitative ChIP data was not convincing. Thus, the mechanisms underlying EGL-9/PHD2 
repression of HIF-1 activity are not well understood. In this dissertation, I have provided some 
important insights into the mechanisms through which EGL-9 suppresses HIF-1 in a 
vhl-1-independent manner. My data show that the prolyl hydroxylase function and the MYND zinc 
finger domain are not required for EGL-9 to suppress HIF-1 transcriptional activity, at least for these 
hif-1 targets tested, but it is still not clear which region/domain/structure of EGL-9 is sufficient for the 
vhl-1-independent function of EGL-9. In the analysis of different egl-9 mutant alleles, I found that 
almost all egl-9 mutation alleles had severe defects in both HIF-1 protein and activity regulatory 
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pathways, except for the MYND deletion allele. I identified nine egl-9 mRNA transcripts with 
different abundances (Figure S3 of Chapter2). Some of the mutant alleles may still be able to generate 
some mRNA isoforms and functional proteins so that they have a slightly less severe phenotype such 
as sa330 and ia60 (Figure 5 in chapter 2) (DARBY et al. 1999). However, it is not clear whether the 
effect is due to the changes of egl-9 expression (expression level and splicing difference) or EGL-9 
structure. To further address this question, we need to generate an EGL-9 specific antibody for 
performing western blot analysis to exam EGL-9 proteins in these egl-9 mutants. Additionally, we 
can run reverse transcription PCR to see which egl-9 transcripts are made in those mutants.  
Ideally, we should be able to make a series of egl-9 deletions to see which region is essential 
for the vhl-1-dependent function of egl-9. However, the fact that egl-9 locus makes nine or more 
transcripts suggests that the egl-9 regulatory elements are too complicated. Through a forward genetic 
screen, we have identified a novel gene swan-1 that possibly functions in concert with EGL-9 to 
suppress HIF-1 transcription activity. SWAN-1 belongs to the WD-repeat AN11 protein family. The 
AN11 family of proteins is evolutionarily conserved and includes Petunia AN11, Arabidopsis TTG1, 
zebrafish WDR68, and human HAN11 (DE VETTEN et al. 1997; DRESSEL and HEMLEBEN 2009; 
NISSEN et al. 2006; SKURAT and DIETRICH 2004). WD repeat proteins often serve as scaffolds for the 
assembly of larger protein complexes. Our yeast-two-hybrid and coimmunoprecipitation data showed 
that EGL-9 physically bound to SWAN-1 (Figure 6 in chapter 3). Based on GFP reporter, swan-1 is 
expressed in most tissues except intestinal cells and is located in the cytoplasm (YANG et al. 2006). 
Pegl-9::GFP is expressed more ubiquitously and located in both the nucleus and cytoplasm (DARBY 
et al. 1999).  Interestingly, in a vhl-1 mutant, hif-1 target Pnhr-57::GFP reporter is induced 
exclusively in the intestine where swan-1 is not expressed. It suggests that the tissue specific 
expression pattern of GFP reporter may be due to the differentially expressed swan-1. To further test 
this, we could make swan-1 transgenic animals that specifically express swan-1 in the intestine. If this 
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represses hif-1 target GFP expression in the intestines of vhl-1 mutant animals, we could conclude 
that intestine-specific HIF-1 activity in vhl-1 mutant is due to the lack of swan-1 expression.   
Another interesting finding is that the swan-1 mutant phenotypes were suppressed by mbk-1 
mutation. mbk-1 encodes a DYRK (duel-specificity tyrosine phosphorylation regulated kinase) family 
protein. MBK-1::GFP is mainly located in the nucleus (RAICH et al. 2003), while SWAN-1 is located 
in the cytoplasm (YANG et al. 2006). Therefore, it is possible that there is no direct interaction 
between SWAN-1 and MBK-1 in C. elegans. Since SWAN-1 and MBK-1 homologs interact in other 
species, it is also possible that they interact in C. elegans. It would be very interesting to know the 
molecular mechanism underlying regulation of HIF-1 transcriptional activity by SWAN-1 and 
MBK-1. One model that we propose is that SWAN-1 and EGL-9 form a complex to protect EGL-9 
from the inhibition effect of MBK-1 (Figure 1A). In swan-1 mutant animals, MBK-1 inactivates or 
decreases EGL-9 activity. Consequently, HIF-1 would be activated (Figure 1B). In swan-1 mbk-1 
double mutants, EGL-9 is still active and represses HIF-1 activity (Figure 1C). This model is 
consistent with our data that mbk-1 mutation only suppressed swan-1 mutant phenotype, but didn’t 
suppress egl-9 mutant phenotype. Interestingly, Morita et al. found in human HEK293T cell line, 
SWAN-1 homolog HAN11 suppressed MBK-1 homolog DYRK1A to phosphorylate GLI1 (MORITA 
et al. 2006). We can test this model further by asking (i) whether EGL-9 and MBK-1 interact; (ii) 
whether there is any phosphorylation at EGL-9 in swan-1 mutant; and if yes, (iii) whether the 
phosphorylation sites are required for activating HIF-1 in swan-1 mutant.  
 
How does HIF-1 regulate C. elegans resistance to P. aeruginosa PAO1: C. elegans with egl-9 
loss-of-function is resistant to P. aeruginosa PAO1 fast killing (DARBY et al. 1999; GALLAGHER and 
MANOIL 2001). In this study, I discovered that the resistance of egl-9 mutants to PAO1 of was hif-1 
dependent (Figure 1A in Chapter 3).  The next question would be: How does hif-1 regulate C. 
elegans resistance to P. aeruginosa PAO1 fast killing? 
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The fast killing effect of PAO1 bacteria is due to the toxicity of hydrogen cyanide because 
mutations in the cyanide synthesis pathway completely suppress this effect (table S5 and 
(GALLAGHER and MANOIL 2001). The toxicity of hydrogen cyanide is probably through the 
inhibition oxidative phosphorylation since both of them are cytochrome c oxidase inhibitors. The 
inhibition of oxidative phosphorylation by cyanide poison mimics oxygen deprivation. We reason that 
in egl-9 mutant, over expression of hif-1 targets would protect animals from oxygen deprivation or 
cyanide toxicity (EPSTEIN et al. 2001; SHEN et al. 2006). Similarly, rhy-1 mutant animals also over 
express hif-1 targets (SHEN et al. 2006), and they are also resistant to the fast killing of PAO1 (Table 
1 in Chapter 3). Consistent with this, egl-9 mutant was also found to be resistant to hydrogen sulfide, 
which is another cytochrome c oxidase inhibitor (BUDDE and ROTH 2010; COOPER and BROWN 
2008).  
Interestingly, animals with stabilized HIF-1 by vhl-1 mutation are resistant to hydrogen sulfide 
(BUDDE and ROTH 2010), but not to PAO1 fast killing (Figure 5, Chapte 3). Additionally, 
stabilization of HIF-1 by expression of hif-1(P621G) transgene was not sufficient to increase 
resistance to PAO1 (Figure 1B, Chapter 3). Thus the resistance to hydrogen sulfide is different from 
the resistance to PAO1 fast killing.  
There are three possible explanations for why stabilizing HIF-1 only was not sufficient to confer 
to resistance PAO1 fast killing. First, it is possible that the threshold of expression of hif-1 targets to 
confer to resistance to PAO1 is higher than the actual expression level in a vhl-1 mutant. Expression 
of hif-1 targets is much higher in egl-9 and rhy-1 mutants relative to in a vhl-1 mutant (SHAO et al. 
2009; SHEN et al. 2006). It is not surprising to see both rhy-1 and egl-9 are resistant to PAO1 (Table 1 
of Chapter 3). swan-1 vhl-1 double mutant animals also express hif-1 targets at higher levels and they 
are also resistant to PAO1 fast killing. Second, perhaps, genes that are required for resistance to 
PAO1 fast killing are only induced in an egl-9 mutant, but not in a vhl-1 mutant. The third possibility 
is that tissue specific expression of hif-1 targets may be required for PAO1 resistance. Hif-1 target 
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GFP reporter is only visible in intestine in a vhl-1 mutant, while it is expressed much more broadly in 
egl-9 mutants. Similarly, the swan-1 mutant increases hif-1 target reporter expression in tissues other 
than the intestine in a vhl-1 mutant background, and they are resistant to PAO1 fast killing. We could 
test the first two models by comparing expression of hif-1 targets in vhl-1 and egl-9 mutant using 
cDNA microarray analysis. Once identifying genes that are expressed differently in vhl-1 and egl-9 
mutants, we could use RNAi to knockdown these genes in an egl-9 mutant to see if any are required 
for the resistance to PAO1 fast killing. We could test the third model by (i) tissue specifically 
expressing vhl-1 or swan-1 in swan-1 vhl-1 double mutant animals or (ii) expressing egl-9 using 
tissue specific promoters in egl-9 mutant animals. Those transgenic animals will have lower HIF-1 
functions in the tissues that express vhl-1 or egl-9. The differences of resistance to PAO1 between 
transgenic and non-transgenic animals would tell us in which tissue HIF-1 activity is important for the 
PAO1 fast killing resistance.  
 
CONCLUDING REMARKS 
In this study, I found that C. elegans EGL-9 was a bifunctional protein. It regulates HIF-1 
stability through hydroxylation of the conserved pro621 and suppresses HIF-1 transcriptional activity 
with little requirement of its hydroxylase activity. This broadens our knowledge about EGL-9, which 
was originally thought solely to be an oxygen sensitive hydroxylase. In collaboration with Yi Zhang, I 
also identified a conserved WD repeats encoding gene swan-1 as a hif-1 negative regulator. SWAN-1 
suppressed expression of HIF-1 targets without altering HIF-1 protein levels. In collaboration with Qi 
Ye, I found that EGL-9 bound to SWAN-1 in yeast-two-hybrid and coimmunoprecipitation assays. 
Furthermore, I discovered that mbk-1, a DYRK1 family protein encoding gene, was required for 
HIF-1 activation by swan-1 mutation. These data suggest that EGL-9, SWAN-1 and MBK-1 act in the 
same pathway to regulate expression of HIF-1 targets. The exact molecular mechanism(s) will need to 
be further illustrated. 
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I also found that hif-1 was required for the resistance of egl-9 mutants to a bacterial pathogen P. 
aeruginosa PAO1 fast killing. The fact that stabilized HIF-1 is not sufficient to confer the resistance 
to PAO1 suggests that both EGL-9 functions are involved in the regulation of PAO1 resistance. 
Further studies will need to focus on identifying hif-1 target genes that contribute to the PAO1 
resistance. 
These discoveries further prove that C. elegans is an excellent system to study hif-1 functions 
and regulation network. 
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FIGURE LEGENDS 
Figure 1 A model for EGL-9, SWAN-1 and MBK-1 regulating HIF-1 transcriptional activity A. In a 
stabilized HIF-1 background, EGL-9 and SWAN-1 forms a complex to suppress HIF-1 transcriptional 
activity. B. In a swan-1 mutant, MBK-1 inhibits/dereases EGL-9 effect on the repression of HIF-1.. 
Thus HIF-1 is more activated. C. In swan-1 mbk-1 double mutants, EGL-9 is active and represses 
HIF-1 activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     125
FIGURE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     126
APPENDIX. THE REGULATION OF HYPOXIA INDUCIBLE FACTOR 
(HIF-1) BY LIN-10/LIN-2/LIN-7 COMPLEX  
 
INTRODUCTION 
Oxygen is one of the fundamental factors for most organisms in the world. When animals meet 
low oxygen cencentrations (hypoxia), which can be due to environmental reasons or physiological 
reasons, hypoxia inducible factors (HIFs) will be induced and regulate a variety of genes expression 
to protect animals from hypoxic injury. HIF transcription factors are composed of an oxygen sensitive 
α subunit HIFα (named HIF-1 in C. elegans) and a stable β subunit (HIFβ also called ARNT in 
mammals, or AHA-1 in C. elegans) (JIANG et al. 2001; POWELL-COFFMAN et al. 1998). The stability 
of HIFα is controlled by PHD/EGL-9 hydroxylase (EPSTEIN et al. 2001). Once it is hydroxylated at 
the conserved prolines in the LXXLAP motif, HIFα/HIF-1 will bind to von Hipple Lindau protein 
(pVHL, named VHL-1 in C. elegans), a subunit of E3 ubiquitin ligase, and subject to ubiqitination 
and protease degradation. 
In addition to regulating HIF-1 stability, C. elegans EGL-9 has been shown to suppress HIF-1 
transcriptional activity with little requirement for the hydroxylase activity (SHEN et al. 2006; SHAO 
et al. 2009). In order to further understand the molecular mechanism by which EGL-9 suppresses 
HIF-1 activity, we conducted a yeast-two-hybrid screen using EGL-9 as bait. One gene that comes 
out of the yeast-two-hybrid screen is lin-10.  
LIN-10 is a PDZ and PTB domain containing protein that is homologous to mammalian Munc 
interacting proteins (Mints). LIN-10, LIN-2 and LIN-7 form a large complex functioning to regulate 
EGF receptor LET-23 localization in the primary vulva precursor cell (KAECH et al. 1998; RONGO et 
al. 1998; WHITFIELD et al. 1999).  LIN-10 has also been shown to regulate an AMPA 
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(α-amino-3-hydroxyl-5-methyl-4-isoxazole- propionate) type of glutamate receptor, GLR-1 in 
neurons (RONGO et al. 1998). Loss of function mutations of lin-10 lead to vulva development defect 
and these animals have egg-laying-defect (egl) phenotype, which is shared by egl-9 loss of function 
mutants (KIM and HORVITZ 1990; TRENT et al. 1983).  In a high throughput yeast-two-hybrid screen, 
HIF-1 interacts with LIN-2 (LI et al. 2004). Given those connections, it would be interesting to ask if 
LIN-10 or LIN-2 regulates HIF-1. 
In this study, I tested the hypothesis that knockdown of lin-10, lin-2 or lin-7 by RNAi or 
mutation would affect HIF-1 protein or expression of hif-1 target genes. I found that the expression of 
hif-1 target Pnhr-57::GFP reporter increased in lin-7 RNAi but not in lin-10 or lin-2 RNAi treated 
animals. The HIF-1 protein was also slightly induced in lin-7 RNAi treated animals. The expression 
of Pnhr-57::GFP was not altered in lin-10 or lin-2 mutants in normoxia culture condition. To address 
if lin-10 suppresses HIF-1 activity when HIF-1 protein is stabilized, I generated vhl-1 lin-10 double 
mutants and treated lin-10 mutant with hypoxia. The expression of Pnhr-57::GFP was not 
significantly induced by lin-10 mutation in vhl-1 mutant background or hypoxia condition, which 
suggests that LIN-10 doesn’t suppress HIF-1 activity even when HIF-1 protein is elevated. 
 
MATERIALS AND METHODS 
Strains and culture conditions: C. elegans was grown at 20°C using standard methods (Brenner 1974). 
Strains used in this study include:  
ZG120 [iaIs077(Pnhr-57::gfp+ unc-119)IV] 
ZG175 [iaIs077(Pnhr-57::gfp+ unc-119)IV; hif-1(ia04) V] 
ZG433 [iaIs077(Pnhr-57::gfp+ unc-119)IV; hif-1(ia04) V; iaIs28(hif-1::ha-myc)] 
ZG709 [lin-10(n1853) I; iaIs07(Pnhr-57::gfp+ unc-119)IV;  vhl-1(ok161) X] 
ZG716 [lin-10(n1853) I; iaIs07(Pnhr-57::gfp+ unc-119)IV;  hif-1(ia04) , him-5 (e1490) V] 
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ZG719 [lin-10(n1853) I; iaIs07(Pnhr-57::gfp+ unc-119)IV; him-5 (e1490) V] 
ZG721 [lin-10(n1853) I; iaIs07(Pnhr-57::gfp+ unc-119)IV; iaIs28(hif-1::ha-myc)] 
ZG723 [lin-10(n1853) I; iaIs07(Pnhr-57::gfp+ unc-119)IV;  hif-1(ia04), iaIs28(hif-1::ha-myc)] 
ZG724 [lin-10(1386) I; iaIs07(Pnhr-57::gfp+ unc-119)IV;  hif-1(ia04), iaIs28(hif-1::ha-myc)] 
ZG725 [lin-10(1386) I; iaIs07(Pnhr-57::gfp+ unc-119)IV; egl-9(sa307) V] 
ZG726 [lin-10(1386) I; iaIs07(Pnhr-57::gfp+ unc-119)IV; hif-1(ia04), egl-9(sa307) V] 
ZG728 [iaIs07(Pnhr-57::gfp+ unc-119)IV; lin-2(e1309)V] 
ZG729 [ lin-10(n1386) I; iaIs07(Pnhr-57::gfp+ unc-119)IV;  vhl-1(ok161) X] 
ZG730 [iaIs07(Pnhr-57::gfp+ unc-119)IV; lin-2(n105)V] 
ZG731 [lin-10(1386) I; iaIs07(Pnhr-57::gfp+ unc-119)IV;  hif-1(ia04), vhl-1(ok161) 
iaIs28(hif-1::ha-myc)]  
 
RNAi:  RNAi media plates are regular NGM plate plus IPTG (final concentration 2mM) and 
Carbenicillin (final concentration 25 µg/ml). Control RNAi strain L4440 and specific gene targeted 
RNAi strains were cultured at 37°C for 6-8hours and seeded on RNAi plate. Seeded plates were dried 
over night, and then L4 stage worms were placed and let lay eggs on RNAi plate for 12-16 hours. 
Adult animals were removed from these plates next day.  F1 animals were collected when they reach 
L4 stage. 
 
Westernblot: For each lane on a protein blot, 20 – 100 L4 or young adult animals from 
developmentally synchronized populations were used. For quantifying Pnhr-57::GFP in egl-9 
mutants (except for gk277), 2-5 L4 worms were used.  The samples were boiled in 1x SDS buffer 
[50mM Tris-HCl PH6.8, 10%(v/v) glycerol, 2% (w/v) SDS, 100mM DTT, 0.1% (w/v) bromphenol 
blue] for 10 minutes before loading to 10% or 12% polyacrylamide gels. After separation, proteins 
were transferred to nitrocellulose membranes.  The blots were probed with monoclonal antibodies: 
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GFP antibody (from Roche) at 1:1000 dilution; HA antibody (Cell Signaling Technology clone 6E2) 
at 1:1000 dilution; Mouse anti-myc ascites (clone 9E10) from the Developmental Studies Hybridoma 
Bank at 1:1000 dilution, or AHA-1 antibody (JIANG et al. 2001)  at 1:100 dilution. The secondary 
antibody (goat anti-mouse IgG+IgM from Biorad) was diluted at 1:2000. The relative intensity of 
protein bands were quantified by Image J software.  The statistical significance of differences was 
assessed by t-tests. 
 
Hypoxia treatment: L4 stage animals were put into hypoxia chamber (0.5% oxygen) and treated for 
1hour, 2hours, 3hours or 4hours, and then around 20 animals were collected and boiled for 10 
mintues in 20μl 1xSDS sample buffer.  
 
RESULTS 
Lin-7 RNAi induces the expression of hif-1 target GFP reporter and HIF-1 protein, but lin-2 or lin-10 
RNAi does not: In a high throughput yeast-two-hybrid screen, HIF-1 is found to binding to LIN-2 (LI 
et al. 2004). LIN-2 has been shown to form a complex with LIN-7 and LIN-10 (KAECH et al. 1998). 
The LIN-2, LIN-7 and LIN-10 complex plays a central role in vulval development by regulating EGF 
receptor LET-23 trafficking, therefore, animals with mutations in lin-2, lin-7 or lin-10 have vulval 
development defect and egg-laying-defect phenotype (egl) (KAECH et al. 1998; KIM and HORVITZ 
1990).  The interaction between EGL-9 and LIN-10 and the hif-1-dependent egl phenotype of egl-9 
mutant promote us to investigate if LIN-10 or the complex (LIN-2, LIN-7 and LIN-10) regulates 
HIF-1.   
First, we looked at the expression of hif-1 target Pnhr-57::GFP reporter in lin-2, lin-7 and lin-10 
RNAi knockdown animals. While the expression of GFP did not change in lin-2 or lin-10 knockdown 
animals (data not shown), it consistently increased in lin-7 RNAi treated animals (Figure 1A). 
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To ask if the induction of GFP is hif-1 dependent, I looked at the GFP expression in hif-1(ia04) 
loss of function mutant. As shown in Figure 1A, to a less degree, the GFP was also induced in 
hif-1(ia04) mutant upon lin-7 RNAi treatment. Those data suggest that lin-7 may regulate 
Pnhr-57::GFP reporter in both hif-1 dependent and independent manners.  
Next, we checked if lin-7 regulated HIF-1 protein level or HIF-1 activity. HIF-1 protein was not 
significantly increased in lin-7 RNAi treated animals (Figure 1B)  
 
Loss of function mutation in lin-10, lin-2 or lin-7 does not change HIF-1 at protein level or 
expression of hif-1 targets: To further test whether lin-10, lin-7 and lin-2 regulate HIF-1, we 
investigated the expression of hif-1 target GFP reporter in lin-10, lin-7 and lin-2 loss of function 
mutants. In both lin-10 loss of function mutation alleles n1853 and n1386, the expression levels of 
Pnhr-57::GFP are not significantly changed relative to these in lin-10 wildtype allele (Figure 2A , 2B). 
Similarly, the expression of Pnhr-57::GFP was not significantly changed in lin-2(e1309) or 
lin-7(e1449) loss of function mutants (Figure 2D, 2E). HIF-1 protein levels were also not changed in 
the lin-10(n1853) loss of function mutant (Figure 2C). 
 
Loss of function mutation in lin-10, lin-2 or lin-7 does not increase expression of hif-1 target GFP 
reporter in hypoxia or vhl-1 mutant background: Our data so far have shown that loss of function 
lin-10 either by RNAi treatment or mutation does not significantly change HIF-1 protein or the 
expression of hif-1 target genes in normal oxygen condition (room air). As we know, HIF-1 protein 
level is very low when animals are culture in room air condition. It is possible that the regulatory 
function of lin-10, lin-2 or lin-7 is subtle and undetectable when HIF-1 protein levels are low.  Next 
question we addressed was whether lin-10, lin-2 or lin-7 regulates expression of hif-1 targets when 
HIF-1 protein levels were elevated by hypoxia treatment or in vhl-1(ok161) loss of function mutant.  
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  Expression of Pnhr-57::GFP was induced in wildtype lin-10(+) or loss of function lin-10(n1853) 
mutant strain upon 0.5% oxygen treatment, with the maximum induction after three hours treatment 
(Figure 3A). However, the expression of Pnhr-57::GFP was not significantly different between 
wildtype lin-10(+) and loss of function lin-10(n1853) mutant strains. Consistently, when expression 
of the same GFP reporter was quantified in vhl-1(ok161) background, in which the HIF-1 was 
stabilized (Figure 3E), no difference between wildtype lin-10(+) and the loss of function 
lin-10(n1853) mutant was detected (Figure 3B). Similarly, expression of this GFP reporter was not 
different between wildtype lin-2(+) and the loss of function lin-2(e1309) upon hypoxia treatment, or 
between wildtype vhl-1 and vhl-1 lin-7(e1449) double mutant (Figure 3C, 3D). 
 
Loss of function mutation in lin-10 does not change expression of hif-1 target GFP reporter in egl-9 
loss of function mutant background: So far we showed that loss of function mutation in either lin-10 
or lin-2 did not increase the expression of hif-1 targets in normoxic condition when HIF-1 protein 
levels are low, or in hypoxic condition/vhl-1(ok161) mutation when HIF-1 protein levels are 
increased. These results suggest that LIN-10 is not a HIF-1 negative regulator, which leads us to the 
hypothesis that EGL-9 may bind to and negatively regulate LIN-10, and LIN-10 function as a HIF-1 
positive regulator functioning downstream of EGL-9. To test this, we compared the expression of 
Pnhr-57::GFP in strong loss of function egl-9(sas07) mutation with egl-9(sa307) lin-10(n1853 or 
n1386) double mutation strains. If our hypothesis is correct, the lin-10 loss-of-function mutation 
would suppress egl-9(sa307) phenotype. Our data showed this was not the case. As shown in Figure 4, 
the expression levels of hif-1 target GFP is similar in egl-9 single mutant and egl-9 lin-10 double 
mutant. 
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FIGURE LEGENDS 
 
Figure 1 The effect of knockdown lin-7 by RNAi on expression of hif-1 target reporter and HIF-1 
protein A, B) expression of Pnhr-57::GFP  is increased when hif-1(+) or hif-1(ia04)  animals were 
treated with lin-7 RNAi B) shows the qunatitative expression of Pnhr-57::GFP  in hif-1(+) 
background C)HIF-1 protein level is slightly increased when animals (ZG433) were treated withlin-7 
RNAi (p=0.10) 
 
Figure 2 The effect of lin-10 mutant on expression of hif-1 target GFP reporter and HIF-1 protein 
levels A, B) expression of Pnhr-57::GFP  is not significantly increased in lin-10(n1853)  or 
lin-10(n1386),  Mutant (p=0.24 and 0.15 respectively) C) HIF-1 protein is slightly increased in 
lin-10(n1853) (p=0.07)  D) expression of Pnhr-57::GFP  is slightly but not significantly increased 
in lin-2 mutant (p=0.17) E)The expression of Pnhr-57::GFP is slightly decreased in lin-7(e1449) 
mutant 
 
Figure 3  Expression of HIF-1 or its target GFP reporter is not significantly altered by lin-10 or 
lin-2 loss of function mutation when HIF-1 protein is stabilized by hypoxia or vhl-1(ok161) mutation 
A) expression of Pnhr-57::GFP  is not statistically different between wildtype lin-10(+) and loss of 
function lin-10(n1853) mutation in hypoxic condition B) expression of Pnhr-57::GFP  is not 
significantly different between vhl-2(ok161) lin-10(n1853)  mutant double mutant to vhl-1(ok161) 
single mutant (p=0.39) C) expression of Pnhr-57::GFP is not significantly altered in loss of function 
lin-2(e1309) mutant relative to in wildtype lin-2(+) in hypoxic condition D) Similar expression of 
Pnhr-57::GFPin vhl-1 and vhl-1 lin-7 double mutant E) HIF-1 protein level is similar in 
vhl-1(ok161)single mutant andvhl-1(ok161); lin-10(n1386) double mutant   
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Figure 4 Expression of Pnhr-57::GFP  is  not significantly changed by lin-10 loss of function 
mutation in egl-9(sa307) mutant background (p=0.24 and 0.18 for n1853 allele and n1386 allele 
respectively) 
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